Regulation of Monocyte Nadph Oxidase;Role of Pattern Recognition Receptors by Elsori, Deena H.
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2009
Regulation of Monocyte Nadph Oxidase;Role of
Pattern Recognition Receptors
Deena H. Elsori
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Biology Commons
How does access to this work benefit you? Let us know!
This Dissertation is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Elsori, Deena H., "Regulation of Monocyte Nadph Oxidase;Role of Pattern Recognition Receptors" (2009). ETD Archive. 89.
https://engagedscholarship.csuohio.edu/etdarchive/89
REGULATION OF MONOCYTE NADPH OXIDASE:  ROLE OF PATTERN 
RECOGNITION RECEPTORS 
 
 
DEENA H. ELSORI 
 
 
 
 
Bachelor of Science in Molecular Biology  
Kuwait University  
Kuwait 
July, 2003 
 
 
 
 
 
Submitted in partial fulfillment of requirements for the degree of  
DOCTOR OF PHILOSOPHY IN REGULATORY BIOLOGY 
at the 
CLEVELAND STATE UNIVERSITY 
August, 2009 
  
 
 
 
 
 
 
 
 
© Copyright 2009 by Deena H. Elsori  
 
 
 
 
 
 
 
 
 
 
 
 
This dissertation has been approved for  
the Department of Biological, Geological,  
and Environmental Sciences and for the  
College of Graduate Studies of  
Cleveland State University  
by 
 
                                        Date: 
Martha Cathcart, Ph.D., Cell Biology/CC 
Major Advisor 
 
 
                                        Date: 
Roy Silverstein, Ph.D., Cell Biology/CC 
Advisory Committee Member 
 
 
                                        Date: 
Xiaoxia Li, Ph.D., Immunology/CC 
Advisory Committee Member 
 
 
                                        Date: 
Crystal Weyman, Ph.D., BGES/CSU 
Advisory Committee Member 
 
 
                                        Date: 
Christine Moravec, Ph.D., Molecular Cardiology/CC 
Internal Examiner 
 
 
                                        Date: 
Gary Koski, Ph.D., Immunology/CC 
External Examiner 
 
 
 
 
 
DEDICATION 
 
 
 
 
 
To my loving husband and best friend, 
Ghassan, and my wonderful son, Khalid  
And 
To my parents, siblings and grandparents   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACKNOWLEDGEMENTS 
I would like to thank every one who made this possible and supported me 
throughout this long journey.  I am very grateful for the constructive criticism and 
continuous guidance of my major advisor Dr. Martha Cathcart and the committee 
members, Drs. Roy Silverstein, Crystal Weyman, Xia Xiao Li and Joseph Fontes. 
  I would also like to thank my parents and siblings back home for their unlimited 
support, and their unfailing love and faith in me. I am extremely thankful to my 
outstanding husband for his love and support and being there for me through all these 
years. And last but not least I would like to thank my son, who at the end of this journey 
was my major encouragement and thank you for providing a different meaning for this 
life.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
REGULATION OF MONOCYTE NADPH OXIDASE:  ROLE OF PATTERN 
RECOGNITION RECEPTORS 
 
DEENA H. ELSORI 
ABSTRACT 
 
Activation of the NADPH oxidase enzyme complex results in the production of 
the oxygen free radical, superoxide anion (O2.-). Superoxide anion is critical for host 
defense against fungal and bacterial pathogens and efficient immune responses; however, 
uncontrolled monocyte-derived O2.- may contribute to chronic inflammation and tissue 
injury. We have previously identified several pathways that regulate the activity of 
NADPH oxidase in human monocytes; however, the receptor(s) responsible for the 
activation of NADPH oxidase in primary human monocytes have not yet been 
determined. This study shows that pattern recognition receptors, namely Dectin-1 and 
Complement Receptor 3, are essential for regulating NADPH oxidase activity in 
Zymosan-activated human monocytes. We show that TLR2 and TLR4 are not required 
for NADPH oxidase activation by Zymosan. In addition this study focuses on Dectin-1 
downstream signaling and complex formation with intracellular signaling proteins. Our 
findings in human monocytes are supportive of the prior recognized role of Src and Syk 
tyrosine kinases in regulating Dectin-1-mediated ROS production in murine 
macrophages. Our data also shows that Src and Syk are tyrosine phosphorylated in 
Zymosan- treated cells and that they both regulate each others activity.  Furthermore, we 
focused on Dectin-1 complex formation with intracellular signaling proteins including 
 vi 
 
  
Syk, Src and PKCδ, protein kinases that regulates NADPH oxidase activity in human 
monocytes. This is the first study to show the involvement of PKCδ in Dectin-1 
signaling. We found that the activity of PKCδ is required for its own complex formation 
with Dectin-1 as well as Syk-Dectin-1 interaction. In contrast, Src and Syk inhibitors had 
no effect on PKCδ association with Dectin-1. Blocking the activity of Src inhibited 
phospho-Syk/Dectin-1 complex formation which supports the role of Src in regulating 
Syk tyrosine phosphorylation/activation.  Our data confirms that Dectin-1, a pattern 
recognition receptor, is a key player in the regulation of NADPH oxidase in Zymosan-
activated human monocytes and we introduce PKCδ as a novel player in Dectin-1 
signaling. 
To expand on this project, the study also includes data reporting an endogenous 
pathophysiological protein, osteopontin, as a novel ligand for Dectin-1. We show here 
that osteopontin induces the oxidative burst in monocytes through Dectin-1. We also 
show data supporting binding of osteopontin to Dectin-1.  
Taken together, our study provides new insights into Dectin-1 ligands and 
downstream signaling in primary human monocytes and highlights novel signaling 
pathways utilized in these important cells.  Our findings are relevant for understanding 
the regulation of NADPH oxidase in the innate immune response and in chronic 
inflammatory diseases. 
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CHAPTER I 
INTRODUCTION 
 
1.1 White blood cells: Monocytes       
Monocytes are produced in the bone marrow and this is followed by their release into 
the blood stream. They are phagocytic mononuclear leukocytes. They have a large oval-
shaped nucleus surrounded by a cytoplasm and several organelles. Monocytes are the 
largest cells among white blood cells/leukocytes (15-18 μm) and make up on average 2-
8% of the total leukocyte population (1, 2). In addition to monocytes, leukocytes also 
include neutrophils, basophils, eosinophils, B-lymphocytes and T-lymphocytes. A 
bipotential stem cell termed colony forming unit-granulocyte monocyte (CFU-GM) is 
responsible for the formation of monocytes and granulocytes (2, 3).  CFU-GM is derived 
from a multipotential progenitor cell termed colony forming unit-granulocyte erythroid, 
macrophages, megakaryocyte (CFU-GEMM) that can differentiate into granulocytes, 
monocytes, platelets or erythrocytes. Growth factors such as IL-3 and granulocyte 
macrophage stimulating factor (GM-CSF) direct the differentiation of CFU-GM to 
monocytes or granulocytes. For the differentiation of CFU-GM to monocytes the 
presence of IL-3, GM-CSF and macrophage colony stimulating factor (M-CSF) is 
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required. However, granulocytes are developed by substituting M-CSF with granulocyte 
colony stimulating factor (G-CSF) giving rise to granulocytes (2).  
Monocytes play a major role in host defense. They are capable of migrating to sites of 
infection where they can differentiate to macrophages. Macrophages can destroy 
invading pathogens by phagocytosis followed by releasing proinflammatory mediators. In 
addition, macrophages and another form of differentiated monocytes, dendritic cells, can 
serve as antigen presenting cells. As antigen presenting cells they can expose denatured 
components of an antigen by expressing it on their surface along with human leukocyte 
antigen (HLA) class II molecules to T-cells which then triggers an adaptive immune 
response (3).   
 
1.1.1 In vitro isolation of human monocytes from peripheral blood 
Mononuclear cells including monocytes and lymphocytes are isolated from the 
human peripheral blood using a ficoll-hypaque density separation method (4). One 
method commonly used to separate monocytes from lymphocytes is adherence to plastic 
or glass (5-7).  Monocytes adhere very strongly to plastic and it is difficult to release 
them.  However,  studies have shown that pre-treating the plastic with calf serum before 
plating monocytes made it easier to release them which is usually done by incubating 
them with EDTA in phosphate buffer saline (6). Isolation of monocytes by adherence to 
serum-coated flasks produces monocytes of 90-95% purity which then can be used in in 
vitro experiments. A detailed description of the protocol used to isolate monocytes for 
experiments in this thesis is included in the next chapter. 
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1.2 Leukocyte NADPH oxidase  
The nicotineamide-adenine dinucleotide phosphate (reduced form; NADPH) oxidases 
are a group of plasma membrane-bound enzymes. Over the past years different 
homologues of NADPH oxidases (NOX) have been identified, however, the leukocyte 
NADPH oxidase also known as NOX2 is best studied (8, 9). At first most of the studies 
were done on neutrophil NADPH oxidase (10, 11) but later attention has been drawn to 
monocyte NADPH oxidase which is the focus of our lab (12). NADPH oxidase catalyses 
a reaction that results in the production of superoxide anion (O2.-) by the one-electron 
reduction of molecular oxygen. NADPH oxidase uses NADPH, provided by the pentose 
phosphate pathway as the electron donor:  
NADPH + 2O2                 2O2- + NADPH+ + H+ 
Superoxide anion produced by monocytes is readily converted to more potent reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2), hydroxyl radical (OH.), 
hypochlorite (OCl-) and singlet oxygen (1O2):   
O2- + O2- + 2H+                           H2O2 + O2 
H2O2 + O2-                 OH. + OH- + 1O2 
H2O2 +  Cl- + H+                  HOCl+ H2O 
ROS are responsible for killing bacterial and fungal pathogens. NADPH oxidase is 
also known as the respiratory burst oxidase because the production of O2.- and the more 
potent oxidants during phagocytosis leads to a rise in oxygen consumption. The 
leukocyte NADPH oxidase consists of several subunits which are divided into membrane 
components including flavocytochrome b558 (consisting of gp91 phox/NOX2 and p22 
phox) and cytosolic components including p67phox, p47phox, p40phox and a small 
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guanosine 5’-triphosphate-binding protein Rac1/2 (12, 13). The components of NADPH 
oxidase in neutrophils and monocytes are very similar with the exception that Rac1 is 
present in monocytes and Rac2 in neutrophils (12, 14). The term “phox” stands for 
phagocytic NADPH oxidase. In leukocytes the components of this enzyme complex are 
unassembled, however once the cells are activated the cytosolic components translocate 
to the membrane and form the active enzyme complex. This assembly activates NADPH 
oxidase and results in the production of O2.- , an oxygen free radical (Figure 1). 
 
 
Biochemical Society Transactions (2006) 34, (960-964) 
FIGURE 1. Model of leukocyte NADPH oxidase under basal and activated 
conditions. Activation of the oxidase involves the stimulus-induced translocation of the 
cytosolic subunits p47phox, p67phox, and p40phox and GTP-bound Rac to the 
cytochrome b558 which is composed of gp91phox and p22phox. The assembled oxidase 
can then use NADPH as a substrate for the reduction of molecular oxygen to O2.-.  
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1.3 Role of NADPH oxidase and O2.-  in innate immunity 
To trigger an efficient immune response against invading pathogens our immune 
system has been divided to innate and adaptive immunity which are made up of 
interconnected events. The first line of defense against infectious agents is the innate 
immune response. Innate immune receptors are responsible for the recognition of 
infectious non-self, pathogen-associated, molecular patterns (PAMPs). White blood cells, 
including monocytes, macrophages, dendritic cells, neutrophils, eosinophils, mast cells 
and NK cells are the major players for the innate immune system. They work by secreting 
cytokines and chemokines which regulate the recruitment and activation of immune cells. 
In addition, epithelial cells from organs such as the lung or gastric tract are also part of 
innate immunity (15). Reactive oxygen species (ROS) produced by NADPH oxidase play 
an essential role in innate immune responses against fungal and bacterial infections. In 
addition, granule-derived proteases and modification of the pH produce an environment 
that is essential for the killing of pathogens (16). Superoxide anion is readily converted to 
H2O2 which is a substrate for lactoperoxidase (LPO) to oxidize thiocyanate anions (SCN–
) to hypothiocyanite (HOSCN). HOSCN is a strong antimicrobial agent (17, 18). This is 
used by the epithelium to prevent colonization and infections. H2O2 is also a substrate for 
Myeloproxidase (MPO).  During neutrophil’s respiratory burst, MPO catalyses a reaction 
that results in the production of hypochlorous acid (HOCl) from H2O2 and chloride anion 
(Cl-). This reaction requires heme as a cofactor. MPO also uses H2O2  to oxidize tyrosine 
to tyrosyl radical (19). Neutrophils use Hypochlorous acid and tyrosyl radical to kill 
pathogens such as bacteria. 
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ROS released by the respiratory burst can be damaging to nearby tissues by 
interacting with other factors such as proteins, lipids and nucleic acids. In some tissues, 
NADPH oxidase-induced ROS are produced at concentrations that are not toxic and are 
usually an essential part of their function and regulation of cellular signaling. This 
function is also involved in innate immunity. 
 Toll-like receptors (TLRs) are the most studied pathogen recognition receptors. They 
play a key role in triggering innate immune responses.  It has been recently shown that 
some NADPH oxidase homologues were found to signal downstream of TLRs  (20). For 
example, after LPS activation TLR4 in neutrophils signals through NADPH oxidase 2 
(NOX2) for the activation of NF-κB-mediated gene expression in adjacent lung 
endothelial cells.  This indicates that NOX-mediated ROS production is involved in 
communication between cells and this triggers an appropriate immune response through 
the activation of intracellular downstream signaling. Furthermore, NOX4 has been shown 
to be an essential player in NF-κB-induced cytokine production after LPS binding to 
TLR4. In a recent study it was shown that LPS interaction with TLR4 triggers a direct 
interaction between NOX4 and TLR4 through the C-terminus of NOX4 and the 
intracellular TIR domain of TLR4. This is required for LPS-induced ROS production and 
NF-κB activation (21). NADPH oxidase also signals downstream of the β-glucan 
receptor, Dectin-1, another innate immune receptor. 
Recently, researchers are focusing on studying the role of innate immunity in antiviral 
immune signaling during virus infections.  A study has shown that mice lacking NOX2 
activity demonstrated an accelerated viral clearance of influenza infection (22). In 
addition, in humans inhibition of NOX2 expression in epithelial cells of the airway 
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interfered with innate immune responses in an NF-κB-dependent  manner following 
respiratory Syncytial virus and Sendai virus infections (23).  
1.4 Chronic Granulomatous Disease 
In some cases neutrophils and macrophages can not induce a respiratory burst 
after exposure to bacterial or fungal infections and this is usually due to a defect in one of 
the subunits of NADPH oxidase (NOX2/gp91phox, p22phox, p67phox or p47phox) 
which causes a rare genetic disorder known as chronic granulomatous disease (CGD) 
(24).  
Chronic Granulomatous Disease (CGD) is a rare inherited disease that affects 1 in 
250,000 people in the United States (25). It can be inherited by an X-linked mutation (X-
CGD) or an autosomal recessive form (AR-CGD) (26). Typical symptoms of CGD 
patients include recurrent infections that start in childhood and these patients are more 
susceptible to bacterial and fungal infections especially when the infection is caused by a 
catalase positive pathogen. Fighting the infection leads to chronic inflammation and 
granuloma formation. The X-linked form is caused by point mutations, mainly in the β 
subunit of the gene that codes for the 91 kDa glycoprotein of NADPH oxidase enzyme 
complex (27). This is the most common form of CGD and it accounts for about 60% of 
the cases (Figure 2). The protein of gp91phox is not detectable in patients with X-CGD 
but these patients express normal amounts of mRNA with normal size transcripts. 
Patients with AR-CGD have normal amounts of gp91phox expressed by their 
phagocytic cell; however, they lack the phosphorylated form of p47phox associated with 
NADPH oxidase during the activation of the respiratory burst in neutrophils (28). This 
indicates that the protein is either missing or a kinase responsible for its phosphorylation 
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is defective. Studies later showed that it was due to the absence of p47phox protein (26, 
29). It was also shown that superoxide anion production by NADPH oxidase could be 
restored in vitro using cytosol fractions from the AR-CGD patients and a recombinant 
p47phox protein (30). Deficiency in p47phox protein accounts for ~25% of AR-CGD 
cases, however, mutations in p22phox and p67phox accounts for 5% of AR-CGD cases 
(Figure 2). 
            
FIGURE 2.  Dysfunction of the NADPH oxidase enzyme complex in chronic 
granulomatous disease.  CGD is caused by mutations in NADPH oxidase subunits. 
Most of the cases are caused by a point mutation in gp91 phox (60%) which is the X-
linked form of CGD. Mutations in p22 and p67 phox accounts for 5% of the autosomal 
recessive cases of CGD. Mutations in p47 phox accounts for 25% of autosomal recessive 
cases. In all of the cases the patients are more susceptible to infections due to the lack of 
superoxide anion production. 
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1.5 Chronic inflammation: Atherosclerosis 
In addition to the role of NADPH oxidase- induced O2.- in host defense and protection 
against invading pathogens, its uncontrolled production by monocytes can lead to chronic 
inflammation, specifically atherosclerosis. Atherosclerosis is a chronic inflammatory 
disease of the vessel wall caused by recruitment of macrophages in the vessel wall and 
foam cell formation. The oxidation of lipids is reported to be involved in atherogenesis 
and the progression of lesion formation. It was also shown that macrophages have an 
increased affinity for oxidized LDL (31, 32) and oxidized LDL causes injuries to cells 
(33-35). 
Depending on the developmental level of the lesion, atherosclerotic lesions can be 
divided into 3 stages including: initial stage or fatty streak, intermediate lesion and the 
advanced fibrous plaque. The accumulation of foam cells derived from monocyte-
differentiated macrophages and smooth muscle cells forms the fatty streaks (36). This is 
followed by monocyte and T-lymphocyte recruitment into the lesion by factors such as 
cytokines and chemokines (chemotactic protein-1, MCP-1) and activation of adhesion 
molecules present on the surface of endothelial cells (Figure 3).  
Interestingly, it was recently shown that the progression of an atherosclerotic lesion 
does not only result from the recruitment and accumulation of monocytes in the arterial 
wall but it is also due to their reduced removal from the lesion. A study showed that 
lysophosphatidic acid and platelet-activating factor (factors that promote lesion 
progression) inhibited monocyte conversion to migratory cells and that promoted their 
accumulation in the subendothleium. In the same study, in vivo experiments showed that 
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monocytes and monocyte-derived cells demonstrated little emigration from progressive 
plaques but were more migratory during lesion regression (37). 
 
     1.5.1 LDL oxidation: Role of O2.- 
For many years the focus of our lab was to clarify the role of O2.- in monocyte-mediated 
low density lipoprotein (LDL) oxidation.  Accumulating studies have shown that if 
monocytes were prevented from entering the vessel wall, lesion formation would be 
compromised (38-40). In addition we have shown that both monocytes and neutrophils 
can mediate the oxidation of LDL through O2.-and this was confirmed by showing 
inhibition by superoxide dismutase (SOD). This suggests that superoxide anion 
participates in LDL oxidation, which makes oxidized LDL a pro-atherogenic molecule 
(34). We have also shown that monocyte-mediated LDL oxidation is dependent on 
activation of the monocytes (34, 41) and that although monocyte-derived superoxide 
anion appears to be required for the oxidation of LDL, it was not entirely responsible for 
its oxidation (35). Monocytes in the blood are in resting state but can be exposed to 
different activating agents. After their activation, monocytes adhere to endothelial cells 
on the blood vessel wall and migrate into the adjacent tissue. While residing in the tissue, 
they differentiate to monocyte-derived macrophages. In the tissue, monocytes are 
activated by different factors and one of their immediate responses is the production of 
the potent oxygen free radical, superoxide anion (O2.- ), a product of a reaction catalyzed 
by NADPH oxidase. Monocyte NADPH oxidase is the main source of O2.- in 
atherosclerotic lesions. Superoxide anion results in the oxidation of LDL. Macrophages 
engulf oxidized LDL and form foam cells which can further cause cell injury, smooth 
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muscle proliferation and secretion of cytokines and acceleration of monocyte recruitment 
(Figure 3) (12).  These are the initial steps for atherosclerotic lesion formation. Therefore, 
it is important to understand the regulation of the activity of this enzyme complex to 
prevent atherogenesis. 
 
 
 
 
FIGURE 3. Model depicting some of the biological and biochemical events that 
occur in a blood vessel during atherosclerotic lesion formation. These events include 
monocyte migration into the vessel wall in response to chemotatic signals such as LDL 
and monocyte chemoattractant protein-1 (MCP-1), adhesion of monocytes to endothelial 
cells along the vessel wall, uptake of LDL by monocytes, migration of lipid-filled 
monocytes/macrophages into the intimal space, foam cell formation, cell injury and 
smooth muscle cell proliferation. In addition to reduced monocyte and monocyte-derived 
cells removal from the lesion. 
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1.6 Signaling pathways regulating monocytic NADPH oxidase. 
The cellular mechanisms leading to the activation of NADPH oxidase and production 
of superoxide anion have been the focus of many investigators since the identification of 
the components of this enzyme complex. Activation of NADPH oxidase requires: 1) 
phosphorylation of some proteins in the complex to be phosphorylated, 2) translocation 
of cytosolic components to join membrane components to form the active enzyme 
complex. 
Our lab has identified and studied several signaling pathways that regulate the activity 
and assembly of monocyte NADPH oxidase (Figure 4). In our model we use opsonized 
Zymosan (ZOP) to stimulate monocytes and study active NADPH oxidase. Zymosan is a 
mimic of a yeast pathogen; it is a cell wall preparation of Saccharomyces cerevisiae and 
has been used as a model system for activating the respiratory burst in monocytes and in 
other models of inflammation. ZOP is opsonized or serum-coated Zymosan.  Zymosan is 
composed of β- glucan, mannans, mannoproteins and chitin which are components of 
yeast recognized by the innate immune system. Using ZOP to activate monocytes, our lab 
has shown that the following mechanisms regulate the enzyme’s activity and assembly: 
1) calcium influx and release from intracellular stores (42), 2) protein kinase C α 
(PKCα)-dependent phosphorylation and activation of cytosolic phospholipase A2 
(cPLA2) (43-45), 3) cPLA2 generation of arachidonic acid which regulate p47 and 
p67phox translocation, 4) PCKδ- dependent phosphorylation and translocation of 
p47phox and p67phox (46-48)  and 5) Rac-1 dissociation from rhoGDI followed by its 
translocation to the membrane (14).  However, the receptor(s) responsible for Zymosan 
and ZOP-induced O2.- and for regulating NADPH oxidase activity in primary human 
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monocytes have not yet been determined. This will be the focus of Chapter 2 of this 
thesis. 
 
 
Zymosan/ZOP Zymosan/ZOP 
FIGURE 4.  Regulation of NADPH oxidase in human monocytes. This model 
summarizes the signaling pathways that regulate the assembly and the activation of 
NADPH oxidase in human monocytes. Pathways including calcium influx, 
phosphorylation of cPLA2 by PKCα, arachidonic acid (AA) release, PKCδ-dependent 
phosphorylation of p47phox/p67phox and Rac-1 translocation to the membrane regulate 
NADPH oxidase activity in activated human monocytes. 
 
1.7  Receptors of the innate immune system 
The innate immune system detects pathogens using a group of receptors known as the 
pattern recognition receptors (PRR). PRRs recognize pathogen-associated molecular 
patterns (PAMPs). Different PRRs are distinguished by their expression profile, 
localization (cell surface, cytosolic, secreted into serum and tissue fluids) and function 
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(49). They are divided into three major categories including signaling PRRs, phagocytic 
PRRs and Secreted PRRs. Signaling PRRs are expressed either on the cell surface or 
intracellulary. Activation of pro-inflammatory signaling pathways including NFκB, Jun 
N-terminal kinase (JNK) and p38 MAP kinase is common among this group. The best 
known family of receptors in this category is the Toll-like receptors (TLRs).  
Phagocytic PRRs are mainly expressed on the surface of phagocytic cells such as 
monocytes, macrophages, neutrophils and dendritic cells. These receptors recognize 
PAMPs on pathogens and allow uptake by phagocytosis. Once phagocytosed, these 
pathogens are placed in intracellular lysosomal compartments and further destroyed by 
different mechanisms. In the case of macrophages and dendritic cells, proteins from 
degraded microorganisms are presented as antigens on their surface along with MHC 
molecules which can be recognized by T-cells and stimulates an adaptive immune 
response. Receptors in this category include: Scavenger Receptors, Macrophage Mannose 
Receptor, and the β-Glucan Receptor, Dectin-1 (50). Secreted PRRs include receptors 
such as the mannan-binding lectin (MBL) and peptidoglycan- recognition proteins 
(PGRPs). They can activate complement, opsonize microbial cells and act as accessory 
protein to aid recognition of pathogens by surface PRRs e.g. TLRs. 
PRRs recognize PAMPs by different methods (Figure 5). Receptors such as Dectin-1 
and the mannose receptor bind and recognize PAMPs through direct non-opsonic 
recognition. However, other PRRs such as complement receptors recognize PAMPs 
through non-direct opsonic recognitions. Opsonization is a term used for coating 
pathogens or molecules with proteins or opsonins such as complement, pentraxins and 
surfactant proteins A and D to allow for easier recognition by receptors. And in some 
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cases receptors recognize a pathogen through both opsonic and non-opsonic recognition. 
Pathogen recognition can also occur intracellularly through some members of the TLRs.  
Recognition of PAMPs by different mechanisms ends up in microbial uptake and killing 
and initiation of an efficient immune response (49). 
 
 
FIGURE 5.  Methods of pathogen recognition by pattern-recognition receptors.  
Pathogens such as fungi and bacteria can be recognized directly by PRRs through non-
opsonic recognition or indirectly through opsonic recognition. In some cases recognition 
requires both opsonic and non-opsonic recognition. Some recognition also occurs 
intracellularly within vacuoles.  
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1.7.1 Leukocyte β-Glucan Receptor: Dectin-1  
 The β-glucan receptor Dectin-1 was first identified by Brown and Gordon through 
an expression cloning protocol (51). It is expressed on monocytes, macrophages, 
neutrophils and on subsets of dendritic cells and T-cells (52). Dectin-1 is a type II 
transmembrane receptor that contains one carbohydrate recognition domain (CRD) at the 
C-terminal portion of the protein and an ITAM-like motif in the N-terminal cytoplasmic 
region (53, 54). The CRD of Dectin-1 belongs to the C-type lectin-like subfamily. 
Dectin-1 is considered a non-classical C-type lectin for 2 reasons. First, it lacks a site for 
calcium binding in its lectin-like domain which indicates that it doesn’t require calcium 
for ligand binding and this is not the case for other C-type lectins. The second reason is 
that the ITAM motif of Dectin-1 is not a typical ITAM in that the distal tyrosine residue 
(Tyr-3) in the membrane is not in the YXXL/I sequence, only the membrane proximal 
tyrosine (Tyr15) is located in this sequence (55, 56). Dectin-1 was first identified on 
dendritic cells but was later found to be expressed on monocytes and macrophages as 
well (51). Dectin-1 is specific for β-1,3,-linked and β-1,6-linked glucans, which are 
PAMPs found in fungal and other microbial cell walls. ITAMs were originally 
characterized in T-cell receptors, Fc receptors and NK receptors. Activation of these 
receptors involves ITAM tyrosine phosphorylation by Src kinase and docking of Syk 
kinase on phosphotyrosine residues followed by its activation and finally leading to 
activation of pro-inflammatory signaling pathways.  The presence of the ITAM-like motif 
in Dectin-1 suggests that this receptor signals through Src/Syk tyrosine kinases. The role 
of Dectin-1 in regulating NADPH oxidase and its downstream signaling is the focus of 
Chapter 2 of this thesis. 
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1.8 Osteopontin: a novel ligand for Dectin-1 
1.8.1 Osteopontin structure and biosynthesis 
Osteopontin (OPN) is an acidic secreted glycoprotein with an approximate 
molecular weight of 32 kDa (57). Osteopontin is post translational modified through 
glycosylation (5-6 O-linked and one N-linked oligosaccharides) and variable 
phosphorylation (12 phospho-Ser and one phospho-Thr) and it is also sulphated. 
Interestingly, in rat kidney cells (58) and calcitrol-stimulated mouse JB6 epidermal cells 
(59) OPN is secreted in a non-phosphorylated form.  OPN has a calcium, hydroxyapatite, 
RGD and a thrombin/MMP cleavage site (57). Cleaved fragments of OPN expose new 
domains and may induce different functions. The amino acid sequence of OPN is 
conserved throughout different species including human, rat, mouse and pig. At first, 
OPN was thought to be biosynthesized by cells of the osteoblastic lineage and deposited 
on mineralized matrix; however, it was later shown that several bone marrow-derived 
cells including dendritic cells, macrophages, smooth muscle cells and endothelial cells 
also produce OPN.  
Studies have shown that osteoclasts bind to OPN in vitro through an RGD- avβ3 
integrin binding (60). OPN in the bone accumulates in areas where osteoclasts are 
attached to the underlying mineral surface (61).  Osteopontin also plays a role in bone 
turnover (62).  Furthermore, OPN has been shown to bind to a non-integrin receptor, 
namely the hyaluronan-receptor CD44 (63). Binding of OPN to CD44 was shown to be 
essential for bone resorption (64).  
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1.8.2 Different immune functions of Osteopontin 
Osteopontin (OPN) is expressed by different immune cells including 
monocytes/macrophages, neutrophils and lymphocytes. It has different functions in 
different cells. OPN regulates immune responses by acting as a chemokine and 
promoting cell recruitment to inflammatory sites (65).  It triggers cell attachment through 
its integrin binding domain (RGD) (66) and wound healing (67). In addition, OPN 
mediates cytokine production and cell activation (68). Finally, this protein was shown to 
play an important role in cell survival by regulating apoptosis (68, 69).  
1.8.3 Osteopontin: Role in Atherogenesis  
As mentioned above OPN is a multi-functional molecule expressed by different 
immune cells. It is highly expressed in chronic inflammatory including atherosclerosis 
and it is also over-expressed in autoimmune diseases. During chronic inflammation, OPN 
accumulates in and around inflammatory cells. OPN has been shown to regulate 
atherogenesis by acting as a chemokine and recruiting monocytes/macrophages to 
inflammatory site and through its adhesive properties (RGD sequence) which promotes 
cell attachment through integrin binding. In addition, it modulates cytokine production in 
dendritic cells, monocytes/macrophages and T-cells during chronic inflammation.  OPN 
plasma levels have been used clinically to diagnose different inflammatory diseases 
including cardiovascular disease. In addition to its role as a proinflammatory molecule, 
OPN is an inhibitor of mineralization and vascular calcification (70, 71). 
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1.9 Rationale and Proposal  
The activation of NADPH oxidase in monocytes results in the production of large 
quantities of the highly reactive oxygen species, O2.-. ROS are known to play a major role 
in the pathogenesis of atherosclerosis and studying mechanisms that regulate the activity 
of NADPH oxidase and ROS production provides useful information for designing new 
tools and therapies to control the progression of this chronic inflammatory disease. Our 
lab had identified several pathways that regulate the function and assembly of this 
enzyme complex but the receptors responsible for regulating the Zymosan-induced 
NADPH oxidase activity in human monocyte had not been identified. 
In chapter 2 of this study we tested whether pattern recognition receptors can regulate 
the function of NADPH oxidase and O2.- produced by Zymosan and ZOP-activated 
human monocytes. We looked at the family of Toll-like receptors, TLR-2 and TLR-4, 
and then studied the role of the β-glucan receptor, Dectin-1, in regulating NADPH 
oxidase in human monocytes. In addition, we tested the involvement of complement 
receptors namely Complement Receptor 3 (CR3) in ZOP-activated monocytes. Finally, 
we studied Dectin-1 downstream signaling and complex formation.  
In chapter 3, we address the role of a secreted glycoprotein known as Osteopontin 
as a novel non-microbial ligand for Dectin-1. So far all of the ligands that are used to 
study Dectin-1 function and signaling are of microbial nature. While trying to look for 
novel non-microbial ligands for Dectin-1, OPN was one of the proteins that we wanted to 
test and the reason for that is mainly due to its highly repetitive structural characteristics 
(featuring a pattern of numerous phosphates and sugars). In addition, the fact that this 
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protein is expressed by different immune cells including monocytes and that it regulates 
chronic inflammation, and specifically atherogenesis, made it more interesting for us 
since this is the focus of studies in our lab. Therefore, chapter 3 of this thesis focuses on 
the role of OPN as a ligand for Dectin-1 and activation of NADPH oxidase in human 
monocytes.  
 
 
  
CHAPTER II 
DECTIN-1 SIGNALING IN PRIMARY HUMAN MONOCYTES: REGULATION OF 
NADPH OXIDASE ACTIVITY 
Deena H. Elsori and Martha K. Cathcart 
 
ABSTRACT 
Dectin-1 belongs to the family of pattern recognition receptors and has recently 
been identified as the leukocyte β-glucan receptor. This study shows that both Dectin-1 
and Complement Receptor 3 are essential for regulating NADPH oxidase activity in 
Zymosan-activated human monocytes. In addition, we show that TLR2 and TLR4 are not 
required for NADPH oxidase activation by Zymosan. Activation of NADPH oxidase 
results in the production of the oxygen free radical, superoxide anion (O2.-). Superoxide 
anion is critical for host defense against fungal and bacterial pathogens and efficient 
immune responses; however, uncontrolled monocyte-derived O2.- may contribute to 
chronic inflammation and tissue injury. We have previously identified several proteins 
that regulate the activity of NADPH oxidase in primary human monocytes. In this study 
we focus on Dectin-1 downstream signaling and complex formation with intracellular 
signaling proteins. Our findings in human monocytes are supportive of the prior 
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recognized role of Src and Syk tyrosine kinases in regulating Dectin-1-mediated ROS 
production in murine macrophages. Our data also shows that Src and Syk are tyrosine 
phosphorylated in Zymosan- treated cells and that they both regulate each others activity. 
However, we show for the first time a requirement for a novel PKC family member, 
PKCδ, in Dectin-1 signaling cascade.  Endogenous Dectin-1 forms a complex with 
PKCδ, Syk and Src tyrosine kinase. The activity of PKCδ is required for its complex 
formation with Dectin-1 and it also acts upstream of Syk in Dectin-1 complex formation. 
In contrast, Src and Syk pharmacological inhibitors have no effect on PKCδ/Dectin-1 
complex formation.  
Taken together, our study provides new insights into Dectin-1 downstream 
signaling in primary human monocytes and highlights distinct pathways utilized in these 
important cells in innate immunity. 
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INTRODUCTION 
Blood leukocytes, including monocytes, play a major role in host defense against 
bacterial and fungal pathogens. One of the critical responses of monocytes to a variety of 
stimulating agents is the production of superoxide anion (O2.-) through the activation of 
the NADPH oxidase enzyme complex. O2.- and other reactive oxygen species (ROS) are 
critical for pathogen killing and maintaining efficient host defense.  Individuals that 
inherit a defect in NADPH oxidase activity develop a disorder known as chronic 
granulomatous disease (CGD) and these patients are characterized by life-threatening and 
recurrent infections that usually start in childhood. O2.- produced by activated monocytes 
has also been shown to oxidize lipids, specifically low density lipoproteins (LDL)(35, 44, 
48, 72). The role of oxidized LDL in the development of atherosclerotic lesions and 
progression of atherosclerosis has been well studied.  Therefore it is important to keep a 
balance in the production of superoxide anion to maintain efficient host defense but at the 
same time avoid contributing to chronic inflammatory processes.    
 Monocytic NADPH oxidase has several subunits which are divided into 
membrane components including flavocytochrome b558 (consisting of gp91 phox and 
p22 phox) and cytosolic components including p67phox, p47phox, p40phox and a small 
guanosine 5’-triphosphate-binding protein Rac-1 (12, 13). When monocytes are activated 
the cytosolic components translocate to the membrane to form the active complex of 
NADPH oxidase which will result in O2.-  production (12). Our lab has identified and 
studied several signaling pathways that regulate the function of monocyte NADPH 
oxidase. These mechanisms include calcium release and influx (42), protein kinase C α 
(PKCα)-dependent phosphorylation and activation of cytosolic phospholipase A2 
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(cPLA2) (43-45), PCKδ- dependent phosphorylation and translocation of p47phox and 
p67phox (46-48) and Rac-1 dissociation from rhoGDI followed by its translocation to the 
membrane (14).  In all of these studies opsonized Zymosan (ZOP) was used to activate 
monocytes and identify these signaling pathways; however, the receptor(s) responsible 
for recognizing Zymosan or ZOP and stimulating the above pathways has not been 
identified in primary human monocytes.  
Zymosan is a mimic of a yeast pathogen, it is a cell wall preparation of 
Saccharomyces cerevisiae and has been used as a model system for activating the 
respiratory burst in monocytes and in other models of  inflammation (73). ZOP is 
opsonized or serum-coated Zymosan.  Zymosan is composed of β- glucan, mannans, 
mannoproteins and chitin which are components of yeast recognized by the innate 
immune system. A group of receptors of the innate immune system known as pattern 
recognition receptors (PRR) have been shown to bind to Zymosan particles and trigger 
pro-inflammatory immune responses in mouse macrophages. These receptors include the 
Toll like receptors (TLRs) and the more recently identified β-glucan receptor, Dectin-1. 
In addition, it was shown that complement receptors, namely Complement Receptor 3 
(CR3, Mac-1, αMβ2),  mediate non-opsonic phagocytosis of Zymosan and Mycobacterium 
kansasii and opsonic phagocytosis of ZOP in Chinese hamster ovary cells (74, 75).   
Studies have shown that Zymosan binding to TLR2 and TLR6 triggers the 
activation of NF-κB and production of TNF-α in rat alveolar macrophages and in RAW 
264.7 cells (76-78). In addition, it was shown that phagosomes containing Zymosan 
recruit TLR1, TLR2, and TLR6 (77, 79). Accumulating evidence suggested that 
microbial-induced pro-inflammatory events are dependent on TLRs (80). More recently 
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studies have shown that the C-type lectin receptor, Dectin-1, collaborates with TLRs in 
Zymosan recognition and in initiating immune responses in mouse macrophages (81). To 
date very limited studies have been conducted in primary human monocytes.   
The β-glucan receptor Dectin-1 was first identified by Brown and Gordon (51). It 
is expressed on monocytes, macrophages, neutrophils and on subsets of dendritic cells 
and T-cells (52). Dectin-1 recognizes intact yeast such as Candida albicans and β-glucan 
containing particles such as Zymosan. It is a type II transmembrane receptor with a C-
type lectin domain at the C-terminus and an immunoreceptor tyrosine-based activation 
motif (ITAM)-like signaling motif in the intracellular N-terminus domain (54). ITAMs 
were originally characterized in T-cell receptors, Fc receptors and NK receptors. 
Activation of these receptors involves ITAM tyrosine phosphorylation by Src kinase and 
docking of Syk kinase on phosphotyrosine residues followed by its activation and finally 
leading to activation of pro-inflammatory signaling pathways.   
It is apparent from these studies that TLRs and Dectin-1 are involved in the 
recognition of microbial pathogens and regulation of different immune responses. The 
purpose of this study was to determine whether innate immune receptors such as TLRs or 
Dectin-1 are involved in triggering the activity of NADPH oxidase in primary human 
monocytes.  In particular we were interested in investigating the role of the above 
receptors in stimulating superoxide production in human monocytes activated by 
Zymosan or ZOP.  Our results indicate that TLR2 and TLR4 are not involved in inducing 
O2.-  in Zymosan or ZOP-activated monocytes; however, we show that Dectin-1 and CR3 
regulate Zymosan and ZOP-induced O2.- release.  We further show that Zymosan induces 
tyrosine phosphorylation of Dectin-1, Syk and Src kinase. Using laminarin, a soluble β- 
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glucan and a Dectin-1 inhibitor, we show that Dectin-1 regulates Src and Syk activity in 
Zymosan-induced monocytes.  In additional studies using Src and Syk-selective 
inhibitors we show that both of these tyrosine kinases regulate NADPH oxidase in human 
monocytes. Finally, we show that PKCδ, Src and Syk form a complex with Dectin-1 and 
this complex formation is regulated by Zymosan and PKCδ activity.  Taken together, our 
data indicate that pattern recognition receptors are required for monocyte NADPH 
oxidase activity in primary human monocytes. 
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MATERIALS AND METHODS 
Reagents 
 Zymosan was purchased from MP Biomedicals (Solon, OH). Abs specific for Src 
phosphorylated on Tyr416 (polyclonal Ab) and for Syk phosphorylated on Tyr525/526 (both 
polyclonal and monoclonal Abs) and Phospho-(Ser/Thr) Phe antibody were obtained 
from Cell Signaling Technology (Danvers, MA). Abs to c-Src (SRC 2) and Syk (4D10) 
were obtained from Santa Cruz Biotechnology (Santa Cruz, California) and PKCδ 
polyclonal antibody. Pharmacological inhibitors such as PP2, PP3, SU6656, oxindole, 
Piceatannol and Rottlerin were purchased from Calbiochem (San Diego, California). The 
inhibitors were dissolved in DMSO and stored at –20°C as stock solutions. Blocking 
antibody to human Toll-like receptor 2 (Mouse monoclonal Ab, clone TL2.1) was 
purchased from HyCult Biotechnology (Uden, The Netherlands). Mouse anti-human 
Complement Receptor 3 (CR3) blocking antibody was obtained from USBiological 
(Swampscott, MA). TLR4 agonist (Ultra pure E.coli 0111:B4 LPS), TLR4 antagonist 
(E.coli K12 msbB LPS) and TLR2 agonist (E.coli 0111:B4 peptidoglycan) were all 
purchased from InvivoGen (San Diego, California). Laminarin was purchased from 
Sigma (St. Louis, MO). Anti-phosphotyrosine antibody (PY99) was purchased from 
Santa Cruz Biotechnology. Human Dectin-1 monoclonal (clone 259931) and goat 
polyclonal antibodies were purchased from R&D Systems (Minneapolis, MN). The 
ExactaCruz Kit was purchased from Santa Cruz Biotechnology (Santa Cruz, California).     
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Preparation of opsonized Zymosan (ZOP) 
  To obtain serum, blood from a healthy donor was collected and allowed to clot at 37ºC 
for 30 minutes. This was followed by spinning the blood at 524x g for 20 minutes and 
collecting the supernatant serum. Zymosan was reconstituted in PBS and boiled for 1 
hour. Zymosan was pelleted at 931 x g and then washed two times with PBS. This was 
followed by incubation of 1 volume of the Zymosan pellet with 3 volumes of fresh serum 
for 20 minutes at 37ºC with frequent mixing. The ZOP was then pelleted by 
centrifugation and washed two times with PBS. ZOP was resuspended in PBS to a final 
concentration of 40 mg/ml and aliquots were stored at -20ºC (72).   
Isolation of human monocytes and cell culture 
 Human monocytes were isolated and purified from whole blood as described previously 
(48, 82). PBS-diluted whole blood was layered over a Ficoll-Paque density solution and 
centrifuged. The mononuclear cell layer was collected and washed twice with PBS, and 
contaminating platelets were removed by centrifugation (280 xg) through bovine calf 
serum (BCS) after overlaying the serum with the mononuclear cells. This serum spin was 
repeated twice. Monocytes were isolated from the platelet-free mononuclear cells by 
adherence to flasks precoated with BCS and containing DMEM and 10% BCS 
(BCS/DMEM). The flasks were incubated for 2 h at 37°C in 10% CO2. Non-adherent 
cells were removed by washing the flasks with BCS/DMEM. Adherent cells were 
detached with PBS containing 5 mM EDTA. The monocytes were collected, washed 
three times with BCS/DMEM, resuspended in BCS/DMEM, and incubated at 37°C in 
10% CO2 for at least 2 h before their use in experiments. In some of the experiments 
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monocytes were isolated from human peripheral blood using a countercurrent centrifugal 
elutriation method (83, 84). Monocyte preparations purified by both methods were very 
similar in response to Zymosan or opsonized Zymosan (ZOP) and are consistently >90% 
CD14+. ZOP or Zymosan were used to activate the monocytes by protocols previously 
described (72).  
Treatment of cells with pharmacological inhibitors 
 Monocytes were plated at a concentration of 5.0 x 106/2 ml/well in six-well plates. The 
cells were treated for 30 minutes with or without one of the following inhibitors: PP2, a 
Src activity inhibitor, PP3 (an inactive analog to PP2), Syk inhibitor (oxindole), 
Piceatannol or Rottlerin at the indicated concentrations. After inhibitor treatment, 
monocytes were left unactivated or were activated with Zymosan or ZOP. Cells were 
collected and lysed as described below.  
Western blots  
Monocytes were scraped from the dish and lysed. Post-nuclear lysates were prepared 
using a lysis buffer containing 1% Triton X 100, NaCl 150 mM, NaF 50 mM, β 
glycerophosphate 30 mM, phosphoserine 0.5 mM, phosphotyrosine 0.5 mM, 
phosphothreonine 1.0 mM, p-nitrophenylphosphate 1.5 mM, Tris pH 7.4 50mM, sodium 
orthovanadate 1 mM, phenylmethylsulfonyl fluoride 500 μM and protease inhibitor 
cocktail (1:50, Sigma Chemical Co.).  After 30 min incubation on ice, extracts were 
centrifuged at 9300 x g for 10 min at 4 ºC, the supernatant was collected and the protein 
concentration was determined. Post-nuclear lysates were resolved by 8% or 10% SDS-
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PAGE and transferred to a PVDF membrane (0.2 µm; Bio-Rad, Richmond, CA). 
Nonspecific binding sites were blocked with 5% BSA in PBST (1X Phosphate-Buffered 
Saline/Tween-20 (0.1%) ) at room temperature for 1 h. Human phospho-Src and 
phospho-Syk were detected with rabbit anti-human polyclonal Abs (Diluted 1/1000 in 
PBST with 3% BSA), followed by incubation with an HRP-conjugated goat anti-rabbit 
IgG (1/500 in PBST with 3% BSA; from KPL, Gaithersburg, Maryland). In the 
immunoprecipitation studies the membrane was incubated with an anti-human PKCδ 
polyclonal Ab, Syk monoclonal Ab or a goat polyclonal Dectin-1 Ab (Diluted 1/1000 in 
PBST with 3% BSA). The membrane was developed using Enhanced 
Chemiluminescence Detection reagents (Pierce).   
Immunoprecipitation 
 Monocytes were pre-treated with the indicated inhibitors for 30 minutes prior to 
Zymosan stimulation (2 mg/ml) for 15 minutes. Post nuclear lysates were prepared as 
described above. The ExactaCruz Kit was used in immunoprecipitation experiments to 
prevent detection of the Heavy and Light chains of the IP antibody, Dectin-1 mouse 
monoclonal Ab. The IP was carried out by following the instructions provided by the 
Exactacruz Kit. Immunoblots were stripped and reprobed with Dectin-1 antibody to 
evaluate immunoprecipitation and assess equal loading.  
Superoxide anion assay 
This assay measures superoxide anion by quantifying superoxide dismutase (SOD)-
inhibitable cytochrome C reduction.  Human monocytes were plated in 24-well tissue 
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culture plates pretreated with Hank’s BSS containing 10% BCS for 1 h at 37ºC (500 μl 
respectively, 1x106/ml in Hank’s BSS 1X) and allowed to adhere for at least two hours. 
This was followed by treatment with the different inhibitors using several concentrations 
at indicated incubation times.  Cytochrome C (160 U/ml, Sigma), with or without 
superoxide dismutase (300 U/ml, Sigma), was added to the wells. This was followed by 
Zymosan or ZOP stimulation. The cells were incubated for 1 h at 37°C. The media was 
collected in tubes and the absorbance of the supernatant was read in cuvettes at 550nm.  
The SOD-inhibitable O2.-   produced by monocytes was calculated by subtracting the 
+SOD values from the −SOD values.  These values were then multiplied by the 
extinction coefficient of 47.6 (read in a cuvette) and expressed as nanomoles/hr/106 cells. 
This method is a modification (46, 47, 72) of an assay previously published by Pick and 
Mizel (85). The following equation was used to determine the nmols of O2.- produced:  
O2.- nmols/ml= (A550 (in the absence of SOD) X 47.6) – (A550 (in the presence of SOD) X 
47.6) 
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RESULTS 
NADPH oxidase activity in Zymosan or ZOP-stimulated human monocytes is independent 
of TLR4 and TLR2 
Previous studies have shown that Zymosan induces inflammatory signals through 
binding to members of the Toll-like receptor family in mouse macrophages (78). 
Therefore in this study we decided to determine whether TLRs might be involved in 
regulating Zymosan and ZOP-induced O2.-  production in primary human monocytes. We 
first tested the role of TLR4.  Figure 6A shows that a TLR4 antagonist did not block 
Zymosan or ZOP-induced O2.- production. We also induced O2.-  with LPS, a known 
TLR4 ligand, in the presence or absence of the TLR4 antagonist. Monocyte O2.-  
production was increased after LPS stimulation and this increase was significantly 
blocked in the presence of this TLR4 antagonist (p<0.01). These results indicate that 
TLR4 signaling is not required for Zymosan or ZOP-induced O2.-  production in 
monocytes. 
Studies have shown that TLR2 binds directly to Zymosan and this triggers NF-қB 
activation and TNF-α and IL-12 secretion in mouse macrophages and dendritic cells  (76, 
81). It was also shown that Zymosan, but not the TLR4 ligand LPS, inhibits IFN-gamma-
induced killing of Mycobacterium bovis Bacillus Calmette-Guérin (BCG) in bone 
marrow-derived mouse macrophages and in a mouse cell line (86).  Therefore, we 
investigated whether a monoclonal antibody recognizing a TLR2-associated epitope 
(TL2.1) would block NADPH oxidase activity in Zymosan or ZOP-induced cells. The 
effect of the function blocking TLR2 antibody on Zymosan-stimulated cells is shown in 
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Fig. 6B. Cells were pretreated with TLR2 blocking antibody for 1 hour followed by 
stimulation with Zymosan for 1 hour, which is the time frame we use when measuring 
O2.-  release in human monocytes. Our lab has previously reported that the peak of O2.-  
production in monocytes is 1 hour after activation (35).  Peptidoglycan (PGN) from gram 
positive bacteria is a known TLR2 ligand (87) and a potent activator of NF-κB and TNF-
α (88). We tested the ability of PGN to induce O2.- production in the presence and 
absence of the TLR2 blocking Ab.  In Fig. 6C the same experiment was carried out but 
the cells were activated with ZOP for 1 hour. Data from these experiments are shown in 
Fig. 6B and 6C. The results demonstrate that treatment with the TLR2 blocking antibody 
did not affect O2.- production in Zymosan or ZOP activated cells. We show that PGN is a 
potent stimulator of NADPH oxidase in human monocytes and this was used as a control 
for the TLR2 blocking antibody. In contrast to ZOP and Zymosan, we show that the 
PGN-induced O2.-  production in human monocytes is inhibited by the TLR2 blocking 
antibody (p<0.05).  Taken together the data in Figure 6 suggest that Zymosan or ZOP do 
not signal through TLR4 for O2.- production in primary human monocytes. In addition, 
TLR2 does not regulate O2.-  production in Zymosan or ZOP activated cells. As expected, 
LPS and PGN trigger O2.- production through TLR4 and TLR2 in human monocytes.   
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FIGURE 6. TLR4 and TLR2 are not involved in Zymosan or ZOP-induced O2.- 
production. A. O2.-  production is not regulated by TLR4 in activated monocytes 
Primary human monocytes were plated in 24-well plates (500μl; 1x106/ml). Monocytes 
were activated with Zymosan (100μg/ml), ZOP (100μg/ml) or LPS (1μg/ml) in the 
presence or absence of the TLR4 antagonist (5μg/ml). Cells were pretreated with the 
antagonist for 30 min. Superoxide anion production was measured during the first hour of 
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activation. Data represent the mean ± SD (n=3) from a representative experiment of four 
independent experiments that were performed. Results were similar in all experiments.   
B. TLR2 is also not involved in Zymosan-induced O2.-  production. Primary monocytes 
were plated as in Fig 6A. Monocytes were left untreated or were treated with a TLR2 
blocking antibody (10μg/ml) for 1 h, followed by stimulation with Zymosan (100μg/ml) 
or E.coli 0111:B4 peptidoglycan (PGN) (5μg/ml). O2.-  production was measured as 
described in Materials and Methods. C. TLR2 is not required for ZOP-induced O2.- 
release.  Monocytes (500μl; 1x106/ml) were treated or left untreated with a TLR2 
blocking antibody (clone TL2.1) for 1 h and then activated with ZOP or PGN. Following 
activation for 1 h O2.- production was measured. Data in A and B represent the mean ± 
SD (n=3) from a representative experiment of three repeat experiments that gave similar 
results. 
 
NADPH activity and superoxide anion production is regulated by the leukocyte β- glucan 
receptor, Dectin-1, and CR3   
Since neither TLR2 nor TLR4 mediated Zymosan or ZOP stimulation of O2.-  
production, we hypothesized that Dectin-1 and/or CR3 might regulate the O2.-  production 
in Zymosan and ZOP-activated monocytes. We therefore proceeded to test the potential  
involvement of the above receptors in NADPH oxidase activity and we were also 
interested in the comparison of receptor utilization between Zymosan and ZOP. 
Laminarin, a soluble β-glucan and a Dectin-1 inhibitor, and a CR3 function 
blocking monoclonal antibody were used to study the roles of Dectin-1 and CR3 in 
Zymosan and ZOP activation of monocyte NADPH oxidase. Both laminarin and anti-
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CR3 blocking antibody were used at maximal inhibitory doses (data not shown). 
Laminarin caused significant inhibition (100% inhibition) of Zymosan-induced O2.- 
production (p<0.01). The CR3 blocking antibody also inhibited O2.-  production 
(p<0.05); however it was not nearly as effective as the Dectin-1 inhibitor in Zymosan-
activated monocytes (30% inhibition) (Fig. 7A). In contrast, in ZOP-activated cells the 
CR3 blocking antibody caused more inhibition (50% inhibition, p<0.01) than laminarin 
(35% inhibition, p<0.05). Finally, we show that a combination of laminarin and anti-CR3 
monoclonal antibody is required to completely block (100% inhibition) O2.- production in 
monocytes stimulated with ZOP and the two together caused additive inhibition (p<0.01) 
(Fig. 7B).  
Taken together, these results suggest that both CR3 and Dectin-1 regulate O2.-  
production in activated primary human monocytes and that Dectin-1 is the predominant 
receptor mediating Zymosan-induced O2.-  production whereas CR3 is the predominant 
receptor mediating ZOP-induced O2.-  production.  
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FIGURE 7. Dectin-1 and complement receptor 3 (CR3) both regulate O2.-  
production in activated human monocytes.   A. Zymosan and ZOP signal through 
Dectin-1 and CR3 for O2.-production in human monocytes. Monocytes were plated as in 
Figure 6A. Monocytes were left untreated or were treated with laminarin (500μg/ml) or 
CR3 (10μg/ml) blocking antibody for 1 h. Monocytes were then activated with ZOP or 
Zymosan (100μg/ml) and O2.- was measured during the first hour of activation. B. In 
ZOP-induced cells CR3 blocking antibody inhibited more than laminarin and the two 
together caused additive inhibition. Cells were activated with ZOP in the presence or 
absence of laminarin or CR3 blocking antibody or a combination of both. Superoxide was 
measured as described previously. Data in A and B show the mean ± SD (n=3) from a 
representative experiment of three that were performed. 
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Zymosan triggers Dectin-1 tyrosine phosphorylation 
Receptors such as T-cell receptors, B-cell receptors and Fc receptors have an 
ITAM motif in their cytoplasmic tail and tyrosine phosphorylation of this motif is 
required for receptor activation and initiation of downstream signaling events. Typically 
ITAMs are tyrosine phosphorylated by Src kinase and this is followed by Syk recruitment 
and autophosphorylation. In addition to the above receptors, it was also shown that 
Dectin-1 has a non-classical ITAM-like motif in its cytoplasmic tail (81, 89). Tyrosine 
phosphorylation of the ITAM-like motif of Dectin-1 is required for Syk recruitment (90). 
Therefore before moving on to study Dectin-1 downstream signaling in monocytes, we 
examined whether Dectin-1 is tyrosine phosphorylated upon stimulation with zymosan in 
primary human monocytes. In Figure 8 monocytes were stimulated with Zymosan, 
lysates were prepared and immunoprecipitated with anti-Dectin-1. Tyrosine 
phosphorylated Dectin-1 was detected by immunoblotting lysates with an anti-
phosphotyrosine antibody, PY99.  
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FIGURE 8. Zymosan triggers Dectin-1 activation. Human monocytes were plated in 
six-well plates at a concentration of 5x106 cells/2ml/well. Monocytes were activated 
using 2 mg/ml Zymosan for 15 min or left untreated. Postnuclear cell lysates were 
prepared, and Dectin-1 was immunoprecipated using a mouse monoclonal antibody 
against Dectin-1. Immunecomplexes were subjected to 10% SDS-PAGE and then 
transferred to PVDF membranes. Dectin-1 immunecomplexes were first immunoblotted 
with an anti-phosphotyrosine antibody (PY99) and then stripped and reprobed with goat 
polyclonal antibody against human Dectin-1 to check immuneprecipitation and equal 
loading. Data were collected from three independent experiments and shown as the mean 
± data range. 
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Zymosan induces tyrosine phosphorylation of Src through Dectin-1 and PP2, SU6656 
inhibit superoxide production in activated monocytes 
We showed earlier that Zymosan requires Dectin-1 for NADPH oxidase activity 
in monocytes and that Dectin-1 is tyrosine phosphorylated in Zymosan-activated 
monocytes. In this study we were interested in looking at Src and Syk activation in 
Zymosan-induced human monocytes. To explore this we conducted studies to test 
whether Zymosan induces Src activation by assessing the auto-phosphorylation of Src 
after Zymosan treatment using a specific antibody that detects Src pTyr416. We activated 
monocytes with Zymosan for 30 minutes and representative results of this treatment on 
Src Tyr-416 phosphorylation are shown in Fig. 9A (upper panel). Zymosan induced Src 
Tyr-416 phosphorylation as compared to inactivated cells. We also tested the effect of 
laminarin and two Syk inhibitors, piceatannol and oxindole, on Src activity. Data shown 
in Fig. 9A (upper panel) demonstrate that blocking Dectin-1 signaling by laminarin 
caused 72% inhibition of Src tyrosine phosphorylation. In addition, Src phosphorylation 
was inhibited 99% by oxindole and 72% by piceatannol. Lane 6 shows cells treated with 
DMSO which was used as a vehicle control and showed no effect on Src activation. We 
then normalized for sample loading as determined by the Src immunoblot (Fig 9A lower 
panel) and graphed the data. 
In Figure 9A we show that Zymosan induces the activation of Src kinase through  
Dectin-1.Therefore, we tested the role of Src in regulating NADPH oxidase activity and 
O2.- production in Zymosan-activated human monocytes. Fig. 9B shows that PP2 and 
SU6656, two specific inhibitors for Src family kinases, dose-dependently inhibited 
Zymosan-triggered O2.- production (p<0.001); however, PP3, the inactive analogue of 
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PP2, had no inhibitory effect. These data suggest an essential role for Src tyrosine kinase 
in controlling NADPH oxidase activity in human monocytes.   
 
 
 41 
 
  
FIGURE 9. Zymosan induces tyrosine phosphorylation of Src kinase through 
Dectin-1 and Src regulates NADPH oxidase activity. A. Src is tyrosine phosphorylated 
in activated monocytes and this event is regulated by Dectin-1 and Syk. Human 
monocytes were plated as in Figure 8. The cells were then left unactivated or were 
activated with Zymosan (2mg/ml) for 30 minutes. The phospho-Src protein was detected 
by Western-blotting using a rabbit anti-human polyclonal phospho-Tyr416-Src antibody. 
In lane 3 the cells were pretreated for 30 min with laminarin (500μg/ml) followed by 
Zymosan activation. In lane 4 and 5 cells were pretreated with two selective Syk 
inhibitors. Lane 6 represents cells pretreated with DMSO alone as vehicle control. After 
activation, cells were lysed and proteins were resolved by SDS-PAGE and 
electrophoretically transferred to a PVDF membrane. The membrane was then subjected 
to Western blot analysis with a p-Src rabbit polyclonal antibody. The membrane was then 
stripped and Src protein was detected using a rabbit anti-human polyclonal antibody 
(lower panel). Data represent results from two independent experiments and are shown as 
the mean ± data range. 
B. PP2 and SU6656 block Zymosan-induced superoxide anion production. Human 
monocytes plated as described in Fig 6A were activated with Zymosan. In some groups 
cells were pretreated with Src inhibitors PP2, SU6656 or PP3, an inactive analogue of 
PP2 at dose dependent manner prior to Zymosan activation. Pre-treatment with the 
inhibitors or vehicle solution (2% DMSO final concentration) was done for 1 hour before 
Zymosan activation. Superoxide anion production was measured in the first hour of 
activation as described in Materials and Methods. Data are from a representative 
experiment of four that were performed showing mean ± SD, n=3.     
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Syk is activated in Zymosan-treated cells and Oxindole blocks superoxide production in 
activated monocytes 
After exploring Src activation we performed more experiments to explore whether 
Syk is activated in Zymosan treated cells. Monocytes were incubated with Zymosan for 
30 minutes or they were left untreated. The level of Syk activation was detected by 
western blotting using an antibody that only detects human Syk when phosphorylated at 
Tyr525/526 (Figure 10A and 10B, upper panel). Data presented in Figure 10A (upper 
panel) demonstrate the effect of laminarin on Syk activation. As shown in the figure Syk 
tyrosine phosphorylation was inhibited 97% by laminarin. Furthermore, the selective 
inhibitor for Src activity, PP2, reduced Syk tyrosine phosphorylation in Zymosan 
activated monocytes, whereas the inactive analogue of PP2, PP3, had no effect (Figure 
10B). To check for protein loading both membranes were stripped and reprobed with an 
antibody against Syk. These studies indicate that Syk tyrosine kinase is phosphorylated at 
its activation site by Zymosan and that both Dectin-1 and Src regulate Syk 
phosphorylation.  
A recent study published by Underhill et al. showed that Dectin-1 activates Syk in 
Zymosan-stimulated IFN-γ primed-mouse macrophages and this is important for the 
production of reactive oxygen species but not for phagocytosis (55). Therefore we tested 
the role of Syk in regulating NADPH oxidase activity and O2.- production in Zymosan-
activated human monocytes. Fig. 10C shows that oxindole dose-dependently inhibited 
Zymosan-induced O2.- (p<0.001). Taken together, our results from Figures 9 and 10 
indicate that Zymosan induces Src and Syk tyrosine phosphorylation, two proteins 
believed to be activated downstream of Dectin-1. We show here that Dectin-1 is indeed 
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upstream of Src and Syk and blocking this receptor will block Zymosan-induced 
activation of both kinases. Using specific pharmacological inhibitors, we also show that 
PP2 regulates Syk activity and Oxindoles regulate Src activity. The above data suggest an 
essential role for both Src and Syk tyrosine kinases in controlling NADPH oxidase 
activity in human monocytes.   
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FIGURE 10.  Syk is tyrosine phosphorylated following monocyte activation and Syk 
activity is required for superoxide anion production.  A. Laminarin blocks Syk 
tyrosine phosphorylation in Zymosan-activated monocytes. Phospho-Syk protein was 
detected using a rabbit monoclonal phospho-Syk Tyr525/526 antibody. In lane 3 (upper 
panel), monocytes were pretreated with laminarin (500μg/ml) for 30 minutes. Cells were 
then activated with Zymosan (2mg/ml) for 30 min. After activation cells were lysed and 
lysates were resolved by SDS-PAGE, electrophoretically transferred to a PVDF 
membrane and analyzed by Western blotting. The blot was stripped and reprobed with a 
Syk monoclonal antibody to check for equal protein loading (lower panel). Data were 
collected from two independent experiments and shown as the mean ± data range 
B.  Tyrosine phosphorylation of Syk kinase is regulated by Zymosan and Src activity. 
Monocytes were plated as previously described and then were activated with Zymosan or 
were left unactivated. Cells were lysed, resolved by SDS-PAGE and analyzed by Western 
blot analysis. Phospho-Syk protein was detected using a rabbit polyclonal phospho-Syk 
Tyr525/526 antibody. In lane 3 and 4 (upper panel), monocytes were pretreated with PP2 
(25μM) and PP3 (25μM) for 30 minutes and then activated with Zymosan (2mg/ml) for 
30 min. The blot was stripped and reprobed with a Syk monoclonal antibody to check for 
equal protein loading (lower panel). Data were collected from two independent 
experiments and shown as the mean ± data range  
C. Oxindole blocks Zymosan-induced superoxide anion production in a dose dependent 
manner. Monocytes were plated as described in Figure 6A. Monocytes were pretreated 
with for 30 minutes prior to Zymosan stimulation. Data are from a representative 
experiment of four that were performed showing mean ± SD (n=3) with similar results. 
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Dectin-1 complex formation 
 We have shown that Dectin-1 is required for the activation of Src and Syk 
tyrosine kinases and for the production of superoxide anion in Zymosan-activated human 
monocytes. We are also interested in studying Dectin-1 complex formation with 
intracellular proteins after monocyte activation. To evaluate possible association of 
Src/Syk kinases with Dectin-1, we immunoprecipitated Dectin-1 from untreated and 
Zymosan-treated monocyte cell lysates at different time points and analyzed the SDS-
PAGE blots with antibodies to Src/Syk kinases.  
 Studies from our lab have shown that PKCδ is required for NADPH oxidase 
activation in primary human monocytes (46, 47). Our lab has also shown that PKCδ is 
both serine and tyrosine phosphorylated after treating monocytes with ZOP (47).  From 
the above studies we know that PKCδ regulates NADPH oxidase activity in human 
monocytes.  Therefore, we were interested to see whether PKCδ is also present in a 
complex with Dectin-1 in monocytes.  
Results of these experiments are presented in Figure 11. Src, Syk and PKCδ co-
immunoprecipitated with endogenous Dectin-1. The data indicate that all three proteins 
are endogenously associated with Dectin-1, and association is enhanced upon treatment 
with Zymosan. Association between the receptor and the proteins peaks at 5-10 minutes 
then gradually decreases and by 30 minutes it drops back to basal level of association. 
Reprobing the blot with Dectin-1 antibody confirmed that equal amounts of Dectin-1 
protein were immunoprecipitated from the lysates (Fig.11, bottom panel). Thus Zymosan 
treatment enhances the association of several different proteins with Dectin-1 and this is a 
very rapid event taking place within 5 minutes of monocyte exposure to Zymosan. In 
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addition these data demonstrate for the first time that PKCδ associates with Dectin-1 and 
that Zymosan enhances the formation of this complex. 
 
 
 
FIGURE 11. PKCδ, Src and Syk associate with Dectin-1. Human monocytes (10 
million/group) were treated with Zymosan (2mg/ml) for 5, 10, 15 and 30 minutes or left 
untreated. All groups were lysed and immunoprecipitated with antibody specific to 
human Dectin-1. The immunoprecipitates were analyzed on 8% SDS-PAGE blots and 
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probed with antibodies to PKCδ, Src or Syk. The bottom panel displays the blot from 
subsequent reprobing, after stripping, using an antibody against Dectin-1. Near-equal 
immunoprecipitation of proteins was observed. This is a representative experiment of two 
performed (n=2). 
 
Tyrosine phosphorylation of Dectin-1, Src and Syk kinase follows the same pattern as the 
complex formation 
 We have shown earlier that Dectin-1, Src and Syk are tyrosine phosphorylated 
after Zymosan activation. Here we carried out time course experiments, looking at 
tyrosine phosphorylation of the above proteins at different time points. The purpose of 
these experiments was to know the peak time for tyrosine phosphorylation and compare 
the pattern of activation with that of complex formation (shown in Fig 11). The tyrosine 
phosphorylation status of Dectin-1 was examined by its immunoprecipitation from 
untreated and Zymosan-treated monocyte lysates and then probing with an anti-
phosphotyrosine antibody (PY99) to detect Zymosan-induced changes in tyrosine 
phosphorylation of the immunoprecipitated proteins. We observed that Zymosan 
markedly induced tyrosine phosphorylation of Dectin-1 (as shown earlier), however, the 
peak of phosphorylation was seen between 5-10 minutes although it decreased after that 
it was still detectable at 30 minutes (Fig 12A, upper panel). The blot was then stripped 
and reprobed with Dectin-1 antibody to ensure adequate immunoprecipitation (Fig 12A, 
lower panel). 
 The tyrosine phosphorylation status of Src and Syk were examined using 
antiphospho-Src or Syk antibodies. In these experiments 50μg monocyte post-nuclear 
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lysates from untreated and Zymosan treated (5, 10, 15 and 30 mins) monocytes were run 
on SDS-PAGE, transferred onto a PVDF membrane and blotted with either phospho-Src 
or phospho-Syk antibody. Phosphorylated Src and Syk were only detectable in Zymosan 
treated cells (Fig 12B and Fig 12C, upper panels). The peak phosphorylation for Src and 
Syk was detectable at 5-10 minutes of Zymosan activation and we observe a decrease at 
later time points. This observation is consistent with the pattern of tyrosine 
phosphorylation of Dectin-1. The lower two panels of  Figure 12B and Figure 12C are a 
result of a strip and a reprobe with total Src or Syk antibody, showing almost equal 
loading. 
Thus it appears from these results that Dectin-1, Src and Syk are all activated after 
5 minutes of Zymosan treatment and this activation decreases with time. This is 
consistent with the pattern of Dectin-1 association with Syk and Src.     
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FIGURE 12.  Zymosan induces Dectin-1, Src and Syk phosphorylation in a time 
point fashion. A. Dectin-1 tyrosine phosphorylation. Monocytes (10 million/group) were 
untreated or treated with Zymosan (2mg/ml) for 5-30 minutes, lysed, and 
immunoprecipitated with an antibody specific for Dectin-1. The immunoprecipitated 
proteins were collected on beads and separated on a 10% SDS-PAGE, transferred onto a 
PVDF membrane, and probed with PY-99. The bottom panel shows the stripped and 
reprobed blot with Dectin-1 antibody. B. Src tyrosine phosphorylation. Monocyte lysates 
were prepared from untreated or Zymosan-treated cells at the indicated time points, and 
protein concentrations were determined. Lysate protein (50 µg) from treated or untreated 
monocytes was loaded in adjacent lanes and probed with anti-phospho-Src antibody. The 
lower panel shows the stripped and reprobed blot with Src antibody. C. Syk tyrosine 
phosphorylation. Monocyte lysates were prepared from untreated or Zymosan-treated 
cells at the indicated time points. Lysate protein (50 µg) from treated or untreated 
monocytes was loaded in adjacent lanes and probed with anti-phospho-Syk antibody. The 
lower panel shows the stripped and reprobed blot with Syk antibody. This a 
representative experiment of two performed (n=2). 
 
 
 
 
 
 
 50 
 
  
PKCδ and Dectin-1 signaling 
PKCδ is required for NADPH oxidase activation in primary human monocytes 
(46, 47). From the above studies we have shown that PKCδ is associated with Dectin-1 
and this association is enhanced by Zymosan activation in monocytes. To expand this 
observation we tested the effect of rottlerin, a PKCδ activity inhibitor, on Dectin-1 
complex formation. In addition, we investigated the role of PP2, a Src inhibitor, and 
Oxindole on PKCδ association with Dectin-1. To test this we performed 
immunoprecipitation and Western-blotting experiments. The upper panel of Figure 13A 
confirms our earlier observation that there is already a weak basal level of association 
between Dectin1 and PKCδ which is induced by the addition of Zymosan. In the presence 
of rottlerin, this interaction becomes weaker which leads to the conclusion that PKCδ 
activity is required for this molecular complex formation. The middle panel of Figure 
13A shows that when PKCδ and Dectin-1 form this molecular complex, PKCδ remains in 
its Ser/Thr phosphorylated form (activated form of PKCδ) and again rottlerin down- 
regulates the activity of PKCδ and inhibits the association between the two molecules. 
The bottom panel shows almost equal levels of Dectin1 in the immunoprecipitates.  
Our studies in Figure 10 suggest the involvement of Syk kinase in Dectin-1 
signaling and NADPH oxidase activation in human monocytes. In Figure 11 we show 
Syk association with Dectin-1. We next wanted to determine whether Syk association 
with endogenous Dectin-1 in monocytes is regulated by PKCδ.  Monocytes were treated 
with Zymosan then lysed, and post-nuclear cell lysates were immunoprecipitated with 
anti-Dectin-1 antibody followed by Western blot analysis. As shown in Figure 13B 
Zymosan induced Syk/Dectin-1 complex formation. Pre-treating lysates with rottlerin 
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followed by Zymosan activation markedly reduced Syk/Dectin-1 complex formation, 
suggesting that PKCδ is acting upstream of Syk in this complex formation. We checked 
protein loading by reprobing the blot with Dectin-1 antibody (Fig 13 B, lower panel).  In 
Figure 13C we tested the effect of PP2 and Oxindole on PKCδ association with Dectin-1. 
Cells were pre-treated with PP2/PP3 and Oxindole for 30 minutes before exposure to 
Zymosan for 10 minutes and the immunoprecipitation/Western blotting was carried out. 
Our results from Fig 13C show that both inhibitors had no effect on PKCδ/Dectin-1 
complex formation. This indicates that Syk and Src do not regulate the interaction of 
PKCδ with Dectin-1. Further experiments are required to find out whether PKCδ 
regulates the Src and Dectin-1 complex formation.  
Bijli et al showed that PKCδ mediates the activation of Syk tyrosine kinase and 
that inhibition of PKCδ activity using pharmacological and genetic approaches blocked 
thrombin-induced Syk activation in human endothelial cells (91). In Fig 13B we showed 
that PKCδ regulates Syk association with Dectin-1. We therefore asked the question 
whether PKCδ can regulate Syk activation. To test this we pre-treated monocytes with 
rottlerin for 30 minutes followed by Zymosan activation for 10 minutes and observed the 
level of tyrosine phosphorylation of Syk in untreated, Zymosan-treated and rottlerin pre-
treated cells. In addition, we carried out similar experiments to test the effect of rottlerin 
on Dectin-1 and Src tyrosine phosphorylation. We show in Figure 14 that rottlerin had no 
effect on the Zymosan-induced tyrosine phosphorylation of Syk, Src or Dectin-1. Taken 
together, our data shows that PKCδ regulates Dectin-1 complex formation with Syk and 
Src while having no effect on their tyrosine phosphorylation.   
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FIGURE 13.  PKCδ regulates Syk association with Dectin-1 but Syk and Src have 
no effect on PKCδ association with Dectin-1.  A. PKCδ regulates the Zymosan- 
induced PKCδ/ Dectin-1 complex formation. Monocytes (10 x 10 /group) were left 
untreated or treated with rottlerin (5μM) for 30 minutes prior to Zymosan (2mg/ml) 
stimulation for an additional 10 minutes. Monocyte lysates from untreated or those 
exposed to Zymosan were immunoprecipitated (IP) with a mouse monoclonal antibody 
against human Dectin-1. Immune complexes were subjected to 10% SDS-PAGE and then 
transferred to PVDF membranes. Dectin-1 immune complexes were first immunoblotted 
with rabbit polyclonal antibody against p-Ser/Thr and then stripped and reprobed with 
anti-PKCδ Ab. Finally the blot was reprobed with a goat polyclonal antibody against 
6
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human Dectin-1. B. Syk/Dectin-1 complex formation is regulated by PKCδ.  Monocyt
were plated as in Fig 13A and were left untreated or treated with Rottlerin (5μM) for 30 
minutes prior to Zymosan stimulation for an additional 10 minutes. Cells were lysed 
protein was immunoprecipitated with anti-Dectin-1 Ab and blotted with Syk Ab.  The
blots were reprobed with anti-Dectin-1 polyclonal Ab to assess loading (lower panels). 
C. 
es 
 
 
PP2 and Oxindole had no effect on PKCδ/Dectin-1 complex formation. Monocytes 
were plated as in Fig 13A and were left untreated or treated with PP2, PP3 or oxindole 
(20μM) for 30 minutes prior to Zymosan stimulation for an additional 10 minutes. Cells
were lysed and immunoprecipitated with anti-Dectin-1 Ab and blotted with Syk Ab.  The
blots were reprobed with anti-Dectin-1 polyclonal Ab to assess loading (lower panels). 
This a representative experiment of two performed (n=2). 
 
 
 
 54 
 
  
 
FIGURE 14. PKCδ does not regulate the tyrosine phosphorylation of Dectin-1, Src 
or Syk. A. Rottlerin and Dectin-1 tyrosine phosphorylation. Monocytes (10 x 106/group) 
were untreated, treated with Zymosan (2mg/ml) for 10 minutes with or without rottlerin 
(5μM) pre-treatment (30 minutes), lysed, and immunoprecipitated with an antibody 
specific for Dectin-1. The immunoprecipitated proteins were collected on beads and 
separated on a 10% SDS-PAGE, transferred onto a PVDF membrane, and probed with 
PY-99. The bottom panel shows the stripped and reprobed blot with the Dectin-1 
antibody. This is a representative experiment of three performed (n=3). 
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B. Rottlerin and Src tyrosine phosphorylation. Monocyte lysates were prepared from 
untreated or Zymosan-treated cells with or without rottlerin pre-treatement, and protein 
concentrations were determined. Lysate protein (50 µg) from treated or untreated 
monocytes was loaded in adjacent lanes and probed with anti-phospho-Src antibody. The 
lower panel shows the stripped and reprobed blot with Src antibody. C.  Rottlerin and 
Syk tyrosine phosphorylation. Monocyte lysates were prepared from untreated or 
Zymosan-treated cells with or without rottlerin pre-treatment and protein concentrations 
were determined. Lysate protein (50 µg) from treated or untreated monocytes was loaded 
in adjacent lanes and probed with anti-phospho-Syk antibody. The lower panel shows the 
stripped and reprobed blot with Syk antibody. 
 
Phospho-Syk forms a complex with Dectin-1 and this event is regulated by PP2 and 
Oxindole 
 We have shown in Figure 10B that PP2, a Src kinase activity inhibitor, but not 
PP3 blocks tyrosine phosphorylation of Syk. This indicates that Src acts upstream of Syk 
and that it regulate the activity of Syk kinase. We were interested to know whether 
phospho-Syk can form a complex with Dectin-1 and if Src would regulate this 
interaction.    
 To test this we performed Immunoprecipitation/Western-blotting experiments. 
The upper panel of Figure 15 shows that Zymosan induces phospho-Syk complex 
formation with Dectin-1. In the presence of PP2, this interaction is markedly inhibited. 
PP3, the structural negative analog for PP2, had no effect. In addition, pre-treating the 
cells with Oxindole also significantly reduced this complex formation. The middle panel 
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shows that there is already a weak level of association between Dectin-1 and total Syk, 
which is induced by Zymosan-stimulation. However, PP2 and Oxindole had no inhibitory 
affect on Syk-Dectin-1 complex formation. The bottom panel shows equal level of 
Dectin-1 in the immunoprecipitates. 
Our results are supportive of Figure 10B which demonstrate that Src regulates 
tyrosine phosphorylation of Syk. Here we show that it regulates phospho-Syk complex 
formation with Dectin-1. In addition, we show that Oxindole reduces this complex 
formation. This could be explained by 1) direct inhibition of Syk kinase activity by the 
inhibitor 2) we have shown in the previous results that Src kinase activity is required for 
Zymosan-induced Syk Tyr 525 phosphorylation/activation and Oxindole regulates Src 
kinase activity therefore it would makes sense that Oxindole could regulate the complex 
by inhibiting Src kinase activity. Total Syk complex formation with Dectin-1 was 
induced by Zymosan (as shown before) but was not inhibited by either Oxindole or PP2. 
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FIGURE 15.  Src regulates phospho-Syk association with Dectin-1.   Zymosan 
induces phospho-Syk/ Dectin-1 complex formation and PP2 and Oxindole inhibits this 
event. Monocytes (5 x 106/2 ml) were left untreated or treated with Oxindole, PP2 or PP3 
(20μM) for 30 minutes prior to Zymosan (2mg/ml) stimulation for an additional 15 
minutes. Monocyte lysates from untreated or those exposed to Zymosan were 
immunoprecipitated (IP) with a mouse monoclonal antibody against human Dectin-1. 
Immune complexes were subjected to 10% SDS-PAGE and then transferred to PVDF 
membranes. Dectin-1 immune complexes were first immunoblotted with rabbit 
monoclonal antibody against p-Syk and then stripped and reprobed with anti-Syk Ab. 
Finally the blot was reprobed with a goat polyclonal antibody against human Dectin-1. 
 58 
 
  
 
FIGURE 16.  Regulation of NADPH oxidase by pattern recognition receptors in 
human monocytes. This model summarizes the receptors and signaling pathways that 
regulate the assembly and the activation of NADPH oxidase in human monocytes. 
Previously we have shown that several pathways, including calcium influx, 
phosphorylation of cPLA2 by PKCα, arachidonic acid (AA) release, PKCδ-dependent 
phosphorylation of p47phox/p67phox and Rac-1 translocation to the membrane regulate 
NADPH oxidase activity in activated human monocytes (12, 14, 42, 45-48). In this study 
we show that Dectin-1 and CR3 serve as receptors for ZOP and Zymosan and they both 
regulate the activity of this enzyme complex in vitro. In addition, we have shown that 
Zymosan induces the activation of Syk and Src kinase, two proteins that signal 
downstream of Dectin-1. We have identified a role for Src and Syk kinase in regulating 
the production of superoxide anion and activity of monocyte NADPH oxidase. Finally, 
 59 
 
  
we show that Zymosan induces Dectin-1 complex formation with PKCδ, Syk and Src. 
PKCδ is upstream of Syk in the complex. 
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DISCUSSION 
 The activation of NADPH oxidase and reactive oxygen species production 
through pattern recognition receptors have been studied in various cell lines and bone 
marrow-derived mouse macrophages (55, 74, 81, 92). A key element of ROS production 
in response to stimuli containing β-glucans is the activation of Dectin-1. Activation of 
mouse macrophages and dendritic cells by Zymosan and other yeast particles containing 
β-glucans results in Dectin-1 activation and Src/Syk phosphorylation (55, 81, 93). 
Dectin-1 has also been reported to activate cPLA2 and COX2 expression in mouse 
macrophages (94, 95) and Syk-dependent ERK activation regulates IL-2 and IL-10 
production by dendritic cells stimulated with Zymosan (96).  
To understand the relevance of innate immune receptors in controlling NADPH 
oxidase activity in primary human monocytes, we investigated the oxidative burst in the 
presence and absence of different receptor inhibitors.  Using selective inhibitors and 
blocking antibodies against TLR2, TLR4, CR3 and Dectin-1, we found that Zymosan and 
ZOP signal primarily through Dectin-1 and CR3 for the activation of NADPH oxidase 
and O2.-  production in human monocytes. We show that TLR2 and TLR4 are not required 
for Zymosan or ZOP-induced O2.-  production. These results are consistent with reports 
showing that Zymosan-induced ROS production in mouse macrophages is independent of 
TLR2 and MyD88 (81).   
In addition to our data showing a Dectin-1 requirement for ROS production 
through Zymosan activation, we report that CR3 can contribute to O2.- release in activated 
human monocytes. CR3 was initially characterized for its binding to opsonized particles. 
More recently it has been shown to play a major role in non-opsonic recognition of 
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Zymosan and Mycobacterium kansasii through its lectin binding domains (74) . Using a 
maximal inhibitory dose of a blocking antibody against human CR3, we show in this 
study that blocking CR3 significantly reduced Zymosan and ZOP-induced O2.- 
production. More CR3 involvement was seen with ZOP-treated cells likely because ZOP 
is coated with serum proteins including C3bi, a ligand for CR3. Laminarin did not inhibit 
as much as the CR3 blocking antibody in ZOP-induced cells because we expect that a 
significant amount of O2.- production was triggered through the C3bi binding site (I-
domain) on CR3 which was less engaged in cells activated with unopsonized Zymosan.  
This further supports the fact that CR3 can act as both an opsonic and non-opsonic 
receptor, binding to β-glucan elements of Zymosan and ZOP through the lectin domain 
and to iC3b on ZOP through the I-domain.  
Signaling through ITAM-containing receptors triggers activation and tyrosine 
phosphorylation of their ITAM cytoplasmic domain. A typical ITAM motif has 2 motifs 
arranged as YXXL and phosphorylation of both tyrosine residues in the dual YXXL 
motif is required to activate Syk/ZAP70 and downstream signaling in ITAM receptors; 
however, in the case of the lectin receptors, Dectin-1 and CLEC-2, there is only a single 
YXXL motif in the cytoplasmic tail and tyrosine phosphorylation of this motif is 
sufficient to recruit Syk and initiate immune responses (90, 97). The ITAM motif of 
Dectin-1 is not a typical ITAM in that the distal tyrosine residue in the membrane is not 
in the YXXL/I sequence, only the membrane proximal tyrosine is located in this 
sequence (90).  
Our findings in human monocytes are supportive of the prior recognized role of 
Src and Syk tyrosine kinases in regulating Dectin-1-mediated ROS production in murine 
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macrophages. Our data also show that Src and Syk are tyrosine phosphorylated in 
Zymosan- treated cells and that they both regulate each others activity. The regulation of 
Syk phosphorylation by Src is consistent with that published in another study using IFN-γ 
primed bone marrow-derived mouse macrophages (55). However, in this study we show 
novel evidence of Syk regulating Src activity in Zymosan-activated monocytes in an 
apparent feedback activation loop.    
Previous findings from our lab showed that PKCδ is required for ZOP activation 
of NADPH oxidase activity in primary human monocytes (46, 47) . We also showed that 
PKCδ is an upstream kinase regulating p67 phosphorylation (46) and p47phox 
phosphorylation and translocation (47) which are required for NADPH oxidase activity. 
In this study we show for the first time a requirement for a novel PKC family member in 
Dectin-1 signaling. PKCδ forms a complex with endogenous Dectin-1 and this complex 
is enhanced by Zymosan. In addition PKCδ/Dectin-1 complex formation is regulated by 
rottlerin, a selective inhibitor of PKCδ activity. Our data also indicate that when PKCδ 
and Dectin1 form a molecular complex, PKCδ remains in its Ser/Thr phosphorylated 
form (activated form of PKC delta) and that rottlerin inhibits the association between the 
two molecules. Our lab has shown in an earlier report that rottlerin blocks PKCδ kinase 
activity using an in vitro kinase activity assay (47).  These data provide evidence that 
PKCδ activity is required for PKCδ/Dectin-1 complex formation. Our study also shows 
that endogenous Dectin-1 forms a complex with Syk and Src tyrosine kinases and that 
PKCδ acts upstream of Syk in the complex formation. In contrast, Src and Syk 
pharmacological inhibitors have no effect on PKCδ/Dectin-1 association. 
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We additionally performed time-course experiments for Dectin-1 association with 
PKCδ, Syk and Src and observed rapid association of all three proteins with Dectin-1 
which was detectable at 5 minutes and reduced over time. Our results from these 
experiments demonstrated a similar pattern for the formation of molecular complex.  
Finally, we confirmed that Src regulates the activity of Syk by showing that phospho-Syk 
and Dectin-1 interaction is significantly inhibited by PP2. Oxindole also blocks this 
complex formation presumably through a Src dependent pathway.  
In summary, in this study we introduce for the first time PKCδ as a new player in 
Dectin-1 signaling cascade and show novel data on Dectin-1 complex formation in 
activated human monocytes. Taken together, our results suggest that non-TLR pattern 
recognition receptors are important regulators of NADPH oxidase function in primary 
human monocytes. This provides insight into mechanisms for controlling superoxide 
anion production in human monocytes. 
  
 
CHAPTER III 
OSTEOPONTIN: A NOVEL NON-MICROBIAL LIGAND FOR DECTIN-1 
Deena H. Elsori, Satya P. Yadav and Martha K. Cathcart 
 
ABSTRACT 
Dectin-1 is a well known receptor for β-glucan rich microbial ligands. To date 
non-microbial endogenous ligands for Dectin-1 have not yet been identified. This study 
supports the role of an endogenous glycoprotein, osteopontin (OPN), as a novel ligand 
for Dectin-1. OPN is an acidic phosphorylated adhesion protein. It is a multi-functional 
molecule expressed by different immune cells including monocytes, macrophages, 
neutrophils and T-lymphocytes and it is also highly expressed in chronic inflammatory 
diseases including atherosclerosis. In search for potential novel non-microbial Dectin-1 
ligands, OPN was one of the candidates that we wanted to test due to its highly repetitive 
structural characteristics (featuring a pattern of numerous phosphates and sugars). In 
addition, the fact that osteopontin is expressed by inflammatory cells and that it promotes 
the pathogenesis of atherosclerosis made this protein an even more tantalizing candidate
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In this study we show that osteopontin signals though Dectin-1 for the activation 
of NADPH oxidase and superoxide anion production in human monocytes and this 
activation is inhibited by laminarin, a lectin blocking reagent. Using the method of 
surface plasmon resonance (SPR), we show direct binding of human recombinant OPN to 
Dectin-1 immobilized on a sensor chip.  
CD44, a cell-surface glycoprotein and hyaluronic acid receptor, is also known to 
bind to OPN. To show that laminarin specifically blocks OPN-induced superoxide anion 
through Dectin-1 and not CD44, we used SPR to exclude laminarin binding to CD44. In 
addition we also show that laminarin does not bind to CD36, another pattern recognition 
receptor.   
Taken together, our results suggest that OPN is a novel ligand for Dectin-1. We 
show for the first time that OPN signals through Dectin-1 for the activation of NADPH 
oxidase in primary human monocytes and demonstrate selective binding between the two 
proteins.
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INTRODUCTION 
 
The β-glucan receptor Dectin-1 was first identified by Brown and Gordon (51). It 
is expressed on monocytes, macrophages, neutrophils and on subsets of dendritic cells 
and T-cells (52). It is a type II transmembrane receptor with a C-type lectin domain at the 
C-terminus and an immunoreceptor tyrosine-based activation motif (ITAM)-like 
signaling motif in the intracellular N-terminus domain (54). Dectin-1 recognizes intact 
yeast such as Saccharomyces cerevisiae, fungal pathogens including Candida albicans 
and Pneumocystis carinii, and β-glucan containing particles such as Zymosan ( yeast cell 
wall preparation). Soluble β-glucans such as laminarin and glucan phosphate block the 
binding of Dectin-1 to Zymosan. Dectin-1 binds specifically to β-1,3-linked or both β-
1,3- and β-1,6-linked glucose monomers through the lectin-like domain (53). Dectin-1 
doesn’t have a typical lectin domain in that it binds to glucans in a calcium independent 
manner (51). Dectin-1 also recognizes intact fungal and yeast pathogens through glucan 
binding. (51, 92, 98) 
Non-microbial endogenous ligands recognized by Dectin-1 have yet been 
determined. All of the ligands used to study Dectin-1 function are exogenous β-glucan 
rich particles and intact microorganisms. It is noteworthy to mention that in addition to 
binding to glucans, Dectin-1 binds to a subset of T-lymphocytes and triggers their 
proliferation (51, 54). Soluble glucans do not inhibit Dectin-1 binding to T-cells (51) and 
this endogenous ligand is still not identified. 
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In this study we investigate the role of a non-microbial phosphorylated protein, 
osteopontin, as novel endogenous ligand for Dectin-1. Osteopontin (OPN) is an acidic 
secreted glycoprotein with an approximate molecular weight of 32 kDa (57). Osteopontin 
is post-translationally modified through glycosylation (5-6 O-linked and one N-linked 
oligosaccharides) and variable phosphorylation (12 phospho-Ser and one phospho-Thr) 
and it is also sulphated. Interestingly, in rat kidney cells (58) and calcitrol-stimulated 
mouse JB6 epidermal cells (59) OPN is secreted in a non-phosphorylated form.  OPN has 
a calcium, hydroxyapatite, RGD and a thrombin/MMP cleavage site (57). Cleaved 
fragments of OPN expose new domains and may induce different functions. The amino 
acid sequence of OPN is conserved throughout different species including human, rat, 
mouse and pig. At first, OPN was thought to be synthesized by cells of the osteoblastic 
lineage and deposited on mineralized matrix; however, it was later shown that several 
bone marrow-derived cells including dendritic cells, macrophages, smooth muscle cells 
and endothelial cells also produce OPN.  
OPN binds to different members of the integrin family, αv and β1 integrins, 
through its RGD binding domain. In addition, OPN has been shown to bind to a non-
integrin receptor, namely the hyaluronan-receptor CD44 (63). Binding of OPN to CD44 
was shown to be essential for bone resorption (64).  
Osteopontin (OPN) is expressed by different immune cells including 
monocytes/macrophages, neutrophils and lymphocytes. It has different functions in 
different cells. OPN regulates immune responses by acting as a chemokine and 
promoting cell recruitment to inflammatory sites (65).  It triggers cell attachment through 
its integrin binding domain (RGD) by binding to different members of the integrin family 
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(66). In addition it has been shown to be essential for wound healing (67). OPN mediates 
cytokine production and cell activation (68). Finally, this protein was shown to play an 
important role in cell survival by regulating apoptosis (68, 69). It is highly expressed in 
chronic inflammatory diseases including atherosclerosis (70, 99) and it is also over-
expressed in autoimmune diseases (100).  
During chronic inflammation, OPN accumulates in and around inflammatory 
cells. OPN has been shown to regulate atherogenesis by acting as a chemokine, by 
recruiting monocytes and macrophages to inflammatory sites, and through its adhesive 
properties (RGD sequence) which promotes cell attachment through integrin binding. In 
addition, it modulates cytokine production in dendritic cells, monocytes/macrophages and 
T-cells during chronic inflammation (70).  OPN plasma levels have been used clinically 
to diagnose different inflammatory diseases including cardiovascular disease. In addition 
to its role as a proinflammatory molecule, OPN is an inhibitor of mineralization and 
vascular calcification (99). 
The reason for choosing OPN as a possible ligand for Dectin-1 is mainly due to 
its highly repetitive structural characteristics (featuring a pattern of numerous phosphates 
and sugars). In addition, OPN is expressed in human monocytes and plays a role in the 
pathogenesis of atherosclerosis.  
We investigated the role of OPN in regulating superoxide anion production in a 
Dectin-1 dependent manner by using the SOD-inhibitable Cytochrome C reduction assay. 
In addition, using SPR (Surface Plasmon Resonance) we tested the binding of 
recombinant osteopontin to Dectin-1 immobilized on a chip and excluded laminarin 
binding to CD44 and CD36, another pattern recognition receptor. 
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MATERIALS AND METHODS  
Reagents 
 Zymosan was purchased from MP Biomedicals (Solon, OH). Laminarin and human 
CD44 monoclonal antibody were purchased from Sigma (St. Louis, MO). Human Dectin-
1 monoclonal antibody (clone 259931), Dectin-1, osteopontin and CD44 recombinant 
proteins were purchased from R&D Systems (Minneapolis, MN).Human recombinant 
CD36 was a generous gift from Dr M.Febbraio and Dr R.Silverstein (Cleveland Clinic, 
Cleveland, OH).   
 Preparation of Zymosan 
Zymosan was reconstituted in PBS and boiled for 1 hour. Zymosan was pelleted at 931 x 
g and then washed two times with PBS and resuspended in PBS to a final concentration 
of 40 mg/ml and aliquots were stored at -20ºC (72).   
Isolation of human monocytes and cell culture 
 Human monocytes were isolated and purified from whole blood as described previously 
(48, 82). PBS-diluted whole blood was layered over a Ficoll-Paque density solution and 
centrifuged. The mononuclear cell layer was collected and washed twice with PBS, and 
contaminating platelets were removed by centrifugation (280xg) through bovine calf 
serum (BCS) after overlaying the serum with the mononuclear cells. This serum spin was 
repeated twice. Monocytes were isolated from the platelet-free mononuclear cells by 
adherence to flasks precoated with BCS and containing DMEM and 10% BCS 
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(BCS/DMEM). The flasks were incubated for 2 h at 37°C in 10% CO2. Non-adherent 
cells were removed by washing the flasks with BCS/DMEM. Adherent cells were 
detached with PBS containing 5 mM EDTA. The monocytes were collected, washed 
three times with BCS/DMEM, resuspended in BCS/DMEM, and incubated at 37°C in 
10% CO2 for at least 2 h before their use in experiments. In some of the experiments 
monocytes were isolated from human peripheral blood using a countercurrent centrifugal 
elutriation method (83, 84). Monocyte preparations purified by both methods were very 
similar in response to Zymosan or opsonized Zymosan (ZOP) and are consistently >90% 
CD14+. ZOP or Zymosan were used to activate the monocytes by protocols previously 
described (72).  
Surface plasmon resonance studies (SPR) 
The interaction between Dectin-1 and various ligands was measured using surface 
plasmon resonance (SPR) using a Biacore 3000 instrument (Biacore, Uppsala, Sweden). 
Dectin-1 was covalently coupled via primary amines, at a concentration of 5000 response 
units, to the dextran matrix of CM5 sensor chips. Different concentrations of recombinant 
human osteopontin in Hank’s (HBSS) buffer containing 1 mM CaCl2, 1 mM MgSO4 and 
1 mM MgCl2  were flowed over flow cells on the sensor chip containing Dectin-1 or 
nothing (reference cell). All data were corrected for the response obtained using a blank 
reference flow cell that was activated with EDC/NHS and then blocked with 
ethanolamine. Experiments were performed by injecting the analytes at 20 μl/min for 2 
minutes. The chip surface was regenerated using 2 M NaCl plus 50 mM NaOH. Data 
were analyzed using the BIAevaluation 3.1 program (Biacore, Uppsala, Sweden). 
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RESULTS 
 
Osteopontin triggers superoxide anion production through Dectin-1 
Non-microbial endogenous ligands for Dectin-1 have not yet been identified. We 
have already shown in chapter II that a microbial ligand, yeast Zymosan, induces 
NADPH oxidase activation through Dectin-1 in primary human monocytes. In this 
experiment we tested the role of a non-microbial pathophysiological ligand, osteopontin, 
in regulating the activity of monocyte NADPH oxidase through Dectin-1. 
The effect of laminarin on Zymosan and OPN-stimulated cells is shown in Figure 
17. Monocytes were pre-treated with laminarin for 1 hour followed by stimulation with 
Zymosan or OPN for 1 hour, which is the time frame we use when measuring O2.-  release 
in human monocytes. Our results demonstrate that Dectin-1 regulates OPN- induced O2.- 
production in primary human monocytes. Zymosan signaling through Dectin-1 is 
supportive of our results from chapter II. In Figure 17 we carried out a dose response 
experiment using increasing levels of OPN. OPN concentrations used in this experiment 
are similar to OPN plasma levels found in patients with chronic inflammatory disease. 
Results indicate that increasing OPN concentration increases the level of O2.-  release in 
monocytes and laminarin showed inhibition in all three doses.    
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FIGURE 17.Osteopontin stimulates superoxide anion production through Dectin-1.  
Primary human monocytes were plated in 24-well plates (500μl; 1x106/ml). Monocytes 
were activated with Zymosan (100μg/ml), OPN (5μg/ml) in the presence or absence of 
laminarin (500μg/ml). Cells were pretreated with laminarin for 1 hour. Superoxide anion 
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production was measured during the first hour of activation. Data represent the mean ± 
SD (n=3). 
 
Osteopontin binds to Dectin-1 
 
We wanted to see if Osteopontin binds to Dectin-1 directly. We examined the 
ability of recombinant human Osteopontin to interact with Dectin-1.  A mature 
recombinant human Osteopontin was obtained commercially and based on the N-terminal 
sequencing, the protein encompasses residues IIe 17-Asn 314 and has calculated 
molecular mass of ~ 33 kDa. OPN is post-translationally modified and due to 
glycosylation it migrates at ~ 65 kDa in SDS-PAGE under reducing conditions. The 
DNA sequence used to generate recombinant human Dectin-1 codes for the extracellular 
domain of Dectin-1 (amino acid residues 66-201). Both recombinant proteins were 
expressed in a mouse myeloma cell line, NS0. 
The capacity of Dectin-1 to bind osteopontin and other ligands was tested using 
SPR. Dectin-1 was coupled to the CM5 chip. First we wanted to test the ability of Dectin-
1 binding its own antibody. Figure 18A shows a sensogram that represent strong binding 
of Dectin-1 to human Dectin-1 monoclonal antibody. This was done to confirm the 
efficiency of Dectin-1 immobilization and activation on the chip. Then we tested the 
binding of osteopontin to Dectin-1. A representative set of SPR profiles across a range of 
osteopontin concentrations flowed over Dectin-1 surface was also determined (Figure 
18B). Increasing the concentration of OPN increases its binding to Dectin-1.  The 
average dissociation constant (Kd) value of OPN binding to Dectin-1 which is the 
maximal responses achieved at equilibrium for each OPN concentration was 3.6 nM. In 
Figure 18C we show that posttranslational modification of OPN is required for its 
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efficient binding to Dectin-1. De-glycosylated and De-phosphorylated OPN do not bind 
to Dectin-1 as observed in the sensogram of Figure 18C. 
In Figure 18D we show laminarin binding to Dectin-1, we then injected CD44 and 
CD36 to test their binding to laminarin. No binding was detected between CD44 or CD36 
and laminarin. This was done to confirm exclusive binding of laminarin to Dectin-1 
which confirms our earlier studies that show OPN signaling through Dectin-1 for the 
activation of NADPH oxidase in monocytes. Finally, we tested the binding of OPN to 
CD44 and CD36. In Figure 18E, we show direct binding of OPN to CD44, a known 
receptor of OPN, but no binding to CD36 (used as a negative control). 
 
A) 
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FIGURE 18. Dectin-1 binds directly to OPN. A) A sensorgram presenting binding of 
Dectin-1 antibody (2nM) to immobilized Dectin-1. B) Representative profiles of the SPR 
responses for osteopontin binding (concentrations ranging from 15.6 nM to 500 nM) to 
Dectin-1in Hank’s BSS media. RU indicates response/resonance units. C) Comparing 
OPN, de-lgycosylated OPN and de-phophosrylated OPN (all at 250 nM) binding to 
Dectin-1.   D) Binding of laminarin (2nM) to Dectin-1 followed by injection of CD44 and 
CD36. E) Testing OPN binding to CD44 and CD36. Studies were done using Hank’s 
(HBSS) buffer supplemented with 1 mM CaCl2, 1 mM MgSO4 and 1 mM MgCl2. 
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DISCUSSION 
Dectin-1 is a pattern recognition receptor that binds to β-glucan rich pathogens. 
The present experiments show that Dectin-1 can also bind other types of ligands that are 
non-microbial in nature. We show that osteopontin (OPN), a phosphorylated glycoprotein 
adhesion molecule, is a different type of ligand for Dectin-1. Our studies demonstrate that 
laminarin, a Dectin-1 inhibitor, blocks osteopontin-induced superoxide anion production. 
Osteopontin binds to Dectin-1 recombinant protein and adheres to monocytes after 
activation of additional receptors. 
Lai and coworkers (101) have shown in a recent study that OPN regulates the 
production of superoxide anion production and NADPH oxidase (NOX2) subunit 
accumulation in aortic vascular smooth muscle cells. They show that OPN-derived 
superoxide anion and oxylipids promote upregulation of MMP-9 during high glucose 
conditions in vitro.  In this study we show data supporting the role of OPN in activating 
NADPH oxidase. Our experiments were done using primary human monocytes and we 
were more interested to know whether Dectin-1 is involved in OPN-induced superoxide 
production. The fact that OPN signals through Dectin-1 for the activation of NADPH 
oxidase and ROS production in human monocytes is very relevant because OPN 
promotes the development and progression of atherosclerosis and vascular remodeling 
(99). It is also highly expressed in atherosclerotic lesions and found in association with 
monocyte-derived macrophages and foam cells. It would be interesting to do further 
experiments to identify downstream signaling molecules that regulate OPN signaling 
through Dectin-1 and NADPH oxidase activation.   
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Binding of osteopontin to Dectin-1 was confirmed using the SPR method. Surface 
Plasmon Resonance is a powerful method used to measure interactions between 
biomolecules in real-time without the need to label the interactants. The concept is to 
immobilize one of the interactants (ligand) on the sensor chip and pass the other molecule 
(analyte) in solution over the surface. Binding and dissociation are presented in a graph 
known as the sensogram and levels of association are presented as response/resonance 
units (RUs).  In our experiments Dectin-1 was immobilized on the sensor chip and 
osteopontin at different concentrations was passed over the surface. Binding between the 
two proteins is shown by the sensograms in Figure 18. In the de-glycosylated and de-
phosphorylated form, OPN does not bind to Dectin-1. We confirmed Dectin-1 
immobilization and activation by showing binding to laminarin and Dectin-1 monoclonal 
antibody. Furthermore, OPN binds to CD44 but not to CD36. We also show that 
laminarin does not bind to CD44 or CD36. This information is required to confirm that 
laminarin specifically blocked OPN-induced superoxide through Dectin-1 and not CD44 
or other pattern recognition receptors such as CD36. Additional studies are required to 
determine the exact binding site for OPN recognition on Dectin-1 as our data indicates 
that the β-glucan site is required which is demonstrated by laminarin inhibition but other 
sites are yet to be investigated.  
 Taken together, our study provides new insights into Dectin-1 ligands in primary 
human monocytes and introduces OPN as a novel non-microbial ligand for Dectin-1. 
This study highlights novel findings that are relevant for understanding this pattern 
recognition receptor and its role in the innate immunity and in chronic inflammatory 
diseases.
  
CHAPTER IV 
GENERAL CONCLUSIONS 
 
NADPH oxidase plays an essential role in host defense by catalyzing a reaction 
that results in the production of superoxide anion, an oxygen free radical. Superoxide 
anion readily converts to more toxic derivatives such as H2O2, OH. and 1O2.  These toxic 
substances are responsible for killing pathogens and promoting host defense. A non-
functional NADPH oxidase can lead to chronic infection which is a symptom of chronic 
granulomatous disease (CGD). CGD is a result of NADPH oxidase deficiency. On the 
other hand, uncontrolled production of ROS can lead to chronic inflammation specifically 
atherosclerosis. Therefore, the regulation of this enzyme complex is important to control 
the production of superoxide anion. 
Various studies have developed from attempts to understand the regulation of 
NADPH oxidase and its product superoxide anion.  Current research is focusing on the 
role of pattern recognition receptors in regulating NADPH oxidase and ROS production. 
The first goal of this research project was to address whether pattern recognition 
receptors can regulate Zymosan/ZOP-induced superoxide anion production in primary 
human monocytes. We chose to test the involvement of Toll-like receptors first. 
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Our results demonstrate that neither TLR4 nor TLR2 are required for superoxide 
anion production in Zymosan or ZOP- activated monocytes. We tested the hypothesis 
that the β-glucan receptor, Dectin-1, and CR3 were involved in regulating NADPH 
oxidase activity in Zymosan or ZOP-stimulated monocytes. We show in this study that 
Zymosan signal primarily through Dectin-1 for the production of superoxide anion 
whereas ZOP signals through both Dectin-1 and CR3. In addition, we studied Dectin-1 
downstream signaling in Zymosan-activated monocytes. Our data show that Src and Syk 
tyrosine kinases signal downstream of Dectin-1 and that they regulate the activity of each 
other. Both of these tyrosine kinases are required for Zymosan-induced superoxide anion 
release. Furthermore, we focused on Dectin-1 complex formation with intracellular 
signaling proteins including Syk, Src and PKCδ, protein kinases that regulates NADPH 
oxidase activity in human monocytes. This is the first study to show the involvement of 
PKCδ in Dectin-1 signaling. We found that the activity of PKCδ is required for its own 
complex formation with Dectin-1 as well as Syk-Dectin-1 interaction. In contrast, Src and 
Syk inhibitors had no effect on PKCδ association with Dectin-1. Blocking the activity of 
Src inhibited phospho-Syk/Dectin-1 complex formation which supports the role of Src in 
regulating Syk tyrosine phosphorylation/activation. We believe our data confirms that 
Dectin-1, a pattern recognition receptor, is a key player in the regulation of NADPH 
oxidase in Zymosan-activated human monocytes. Finally, we introduce PKCδ as a novel 
player in Dectin-1 signaling. 
The Second goal of this project was to search for novel, endogenous ligands for 
Dectin-1. Different microbial ligands have been used to study Dectin-1 signaling and 
function; however, non-microbial endogenous ligands for this receptor have not yet been 
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elucidated. We tested the hypothesis that osteopontin, an endogenous pathophysiological 
protein, is a novel ligand for Dectin-1. Our findings suggest for the first time that 
osteopontin triggers superoxide anion production through Dectin-1 in human monocytes. 
This event is inhibited by laminarin, a lectin blocking reagent. We confirm the interaction 
between osteopontin and Dectin-1 by showing direct binding using the technique of 
surface plasmon resonance. Furthermore, we show binding of OPN to CD44, a known 
OPN receptor, and exclude OPN binding to CD36.  Finally, we show that laminarin does 
not bind to CD44 or CD36. Additional studies are required to explore the mechanism and 
downstream signaling events of osteopontin-Dectin-1 interaction. 
In conclusion the data presented in this thesis suggest that pattern recognition 
receptors and their ligands are essential regulators of NADPH oxidase activity in primary 
human monocytes.
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